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BACKGROUND: Several small-scale animal studies have suggested that gut microbiota and blood pressure (BP) are linked. 
However, results from human studies remain scarce and conflicting. We wanted to elucidate the multivariable-adjusted as-
sociation between gut metagenome and BP in a large, representative, well-phenotyped population sample. We performed 
a focused analysis to examine the previously reported inverse associations between sodium intake and Lactobacillus abun-
dance and between Lactobacillus abundance and BP.
METHODS AND RESULTS: We studied a population sample of 6953 Finns aged 25 to 74 years (mean age, 49.2±12.9 years; 
54.9% women). The participants underwent a health examination, which included BP measurement, stool collection, and 
24-hour urine sampling (N=829). Gut microbiota was analyzed using shallow shotgun metagenome sequencing. In age- and 
sex-adjusted models, the α (within-sample) and β (between-sample) diversities of taxonomic composition were strongly re-
lated to BP indexes (P<0.001 for most). In multivariable-adjusted models, β diversity was only associated with diastolic BP 
(P=0.032). However, we observed significant, mainly positive, associations between BP indexes and 45 microbial genera 
(P<0.05), of which 27 belong to the phylum Firmicutes. Interestingly, we found mostly negative associations between 19 
distinct Lactobacillus species and BP indexes (P<0.05). Of these, greater abundance of the known probiotic Lactobacillus 
paracasei was associated with lower mean arterial pressure and lower dietary sodium intake (P<0.001 for both).
CONCLUSIONS: Although the associations between overall gut taxonomic composition and BP are weak, individuals with hy-
pertension demonstrate changes in several genera. We demonstrate strong negative associations of certain Lactobacillus 
species with sodium intake and BP, highlighting the need for experimental studies.
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Dysbiosis of the gut microbiota has been re-cently linked to various chronic diseases, such as obesity, metabolic syndrome, diabetes mel-
litus,1 and cardiovascular disease,2 and changes in 
lifestyle.3 Additional evidence, primarily from animal 
studies, suggests an association between micro-
biota and hypertension.4–7 Furthermore, high salt 
intake, a risk factor for both hypertension and car-
diovascular disease, was shown to deplete certain 
Lactobacillus species in mice while treating the mice 
with Lactobacillus prevented salt-sensitive hyperten-
sion.8 Findings from these studies are consistent with 
those from human studies, in which consumption of 
salted snacks has been indicated as a significant 
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correlate of the human gut microbiota.9 In addi-
tion, the gut microbiota has been functionally linked 
to complications of hypertension, such as arterial 
thrombosis.10–12 These prior results therefore high-
light the potential of the gut microbiota as a thera-
peutic target for hypertension.
Despite these promising results from animal stud-
ies, human data are scarce and conflicting. In the 
TwinsUK cohort,13 self-reported hypertension was not 
related to 68 various microbiota markers. In another 
publication based on a subsample of 529 CARDIA 
(Coronary Artery Risk Development in Young Adults) 
study participants,14 an SD increase in gut microbi-
ota α (within-sample) diversity was related to a mod-
est 1.29  mm  Hg lower systolic blood pressure (BP; 
P=0.049). In a commentary, Jama and coauthors15 
proposed several improvements in the experimental 
design of future studies examining the relation be-
tween the microbiota and hypertension, such as the 
use of standardized BP measurements, adjustment for 
medication use, and replacing 16S rRNA profiling with 
metagenome sequencing.
Herein, we aim to advance the current knowledge 
on the association between the gut metagenome 
and BP in a well-phenotyped, large random pop-
ulation sample of 6953 individuals while adjusting 
for relevant confounders, including antihypertensive 
medication classes. A 24-hour urine sodium sample 
was available for 829 individuals. We therefore also 
performed a more focused analysis on the interre-
lations between sodium intake, gut Lactobacillus 
abundance, and BP to gain additional insight on the 
potential mechanisms through which the microbiota 
might affect BP.8
METHODS
Availability of Data and Materials
The data that support the findings of this study are 
available from Finnish Institute for Health and Welfare 
Biobank (https://thl.fi/en/web/thl-biobank). The data 
are not publicly available because they contain infor-
mation that could compromise research participant 
privacy/consent. The source code for the analyses is 
openly available at 10.5281/zenodo.3622730.
Study Sample
The Finnish Institute for Health and Welfare has 
performed population surveys every 5  years since 
1972 to monitor the development of cardiovascular 
risk factors in the Finnish population.16 A random 
population sample of 13 437 individuals, aged 25 to 
74  years, from 6 geographic regions was invited to 
take part in the FINRISK 2002 study.17 Of the 8799 
individuals who took part in the FINRISK 2002 study 
(participation rate, 65.5%), we excluded 1568 who 
did not provide stool samples, 20 because of low 
total read count (N<50  000), and 258 because of 
missing relevant covariates, for a final study sample 
of 6953 individuals who were included in the anal-
ysis. For a subsample of 829 participants, 24-hour 
urine collection for estimating dietary sodium intake 
was performed.18 The study was approved by the 
Coordinating Ethics Committee of the Helsinki and 
Uusimaa University Hospital District, and all partici-
pants gave written informed consent.
CLINICAL PERSPECTIVE
What Is New?
• We advance the prior scarce and conflicting 
knowledge on the associations between gas-
trointestinal microbes and hypertension in a 
large, representative population sample using 
standardized blood pressure measurements, 
adjustment for relevant confounders, and stool 
metagenomic sequencing.
• Although the associations between overall gut 
taxonomic composition and blood pressure 
are weak, individuals with hypertension dem-
onstrate changes in several microbiota genera, 
with most of these genera belonging to the 
Firmicutes phylum.
• Interestingly, we also demonstrate strong nega-
tive associations of certain Lactobacillus spe-
cies with both dietary sodium intake and blood 
pressure.
What Are the Clinical Implications?
• The observed associations between the gut 
microbial composition and hypertension offer 
novel insights on the potential mechanisms 
through which diet affects the gut microbiome 
and blood pressure.
Nonstandard Abbreviations and Acronyms
BP blood pressure
CARDIA  Coronary Artery Risk Development in 
Young Adults
ICD-8  International Classification of Diseases, 
Eighth Revision
ICD-9  International Classification of Diseases, 
Ninth Revision
ICD-10  International Classification of Diseases, 
Tenth Revision
KO  Kyoto Encyclopedia of Genes and 
Genomes Orthology group
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Health Examination and 24-Hour Urine 
Collection
After completing a questionnaire on sociodemographic 
information, lifestyles, medications, and medical his-
tory at home, the participants attended a physical 
examination at a local study site. The participants un-
derwent measurements for height and weight. A nurse 
measured sitting BP 2 times from the right arm using 
a mercury manometer and a 14×40-cm cuff after a 
5-minute rest. Participants in the 24-hour urinary so-
dium subsample were instructed to start the collection 
on a Sunday morning and return the container the fol-
lowing day. A sample of urine was frozen at −20°C and 
later analyzed using an ion-selective electrode (Optima 
analyzer; Thermo Electron Oy, Vantaa, Finland).18 Urine 
sodium excretion was calculated as the product of 
urine sodium concentration and daily excreted urinary 
volume.
Stool Sampling and Storage
Stool samples were collected at home after the phys-
ical examination in 50-mL Falcon tubes and were 
mailed to Finnish Institute for Health and Welfare 
using prepaid packages over 1 to 2 days. The sam-
ples were then frozen in −20°C and kept unthawed 
until 2017, when they underwent metagenomic 
sequencing.
Stool DNA Extraction and Library 
Preparation
Microbiota analysis was performed at the University of 
California, San Diego, using whole genome untargeted 
shallow shotgun metagenomic sequencing against 
mapped reference databases, following a previously 
published protocol.19 In brief, Illumina-compatible li-
braries were prepared from isolated DNA and normal-
ized to 5-ng input per sample. Samples were pooled 
using the iTru20 dual-indexing system and sequenced 
using Illumina Hi-Seq 4000 for paired-end 150-bp 
reads. Sequence reads were mapped against taxon-
omy using SHOGUN v1.0.5 against National Center for 
Biotechnology Information RefSeq database (version 
82; May 8, 2017).21,22 Functional profiles were calcu-
lated from a combination of observed and predicted 
Kyoto Encyclopedia of Genes and Genomes Orthology 
group (KO) annotations from the RefSeq genomes 
following the predicted parameters of the SHOGUN 
tool.21
Outcome Variables and Covariates
The mean of the 2 measurements was used to de-
termine systolic and diastolic BP. Hypertension was 
defined as systolic BP ≥140  mm  Hg, diastolic BP 
≥90  mm  Hg, or use of antihypertensive medication. 
Pulse pressure was defined as systolic minus diastolic 
BP. Mean arterial pressure was defined as follows: 
[(2×diastolic BP)+systolic BP]/3.
Body mass index was defined as weight (kilograms) 
divided by the square of the body height (meters). 
Participants were asked to assess their leisure-time 
physical activity by a 4-option multiple choice question. 
The 4 options for leisure-time activity were (1) seden-
tary, (2) light activity for >4 hours per week, (3) fitness 
training or other strenuous exercise for >3 hours per 
week, and (4) competitive sports. Information on medi-
cation use was retrieved from the Finnish national Drug 
Purchase Register,23 which captures all prescription 
drug purchases in Finland. Finnish pharmacies fill pre-
scriptions for a maximum of 3 months, and antihyper-
tensive medication use was defined as a drug purchase 
occurring within the 4  months preceding baseline. 
Medications with the following Anatomical Therapeutic 
Chemical classification24 codes were considered anti-
hypertensive medications: diuretics (C03*), β blockers 
(C07*), calcium channel blockers (C08*), and renin–an-
giotensin system inhibitors (C09*). Prevalent diabetes 
mellitus was defined as self-reported diabetes mellitus, 
a previous diagnostic code indicating diabetes mel-
litus in the nationwide Care Register for Health Care 
(International Classification of Diseases, Tenth Revision 
[ICD-10], codes E10-E14 or International Classification 
of Diseases, Eighth Revision/International Classification 
of Diseases, Ninth Revision [ICD-8/ICD-9], code 250), 
a previous diabetes mellitus medication purchase 
(Anatomical Therapeutic Chemical classification code 
A10*), or special reimbursement code for diabetes mel-
litus medications in the Drug Reimbursement Register. 
Smoking was defined by self-reported current daily 
smoking.
Statistical Analysis
We compared characteristics between individuals 
who were and were not included in the urinary so-
dium subsample using the 2-sample T test and the 
χ2 test of equality of means. Unless otherwise noted, 
we adjusted the analyses for age, sex, body mass 
index, smoking, exercise, diabetes mellitus, diuretic 
use, β-blocker use, calcium channel blocker use, 
and renin-angiotensin system inhibitor. We calculated 
α diversity (Shannon index) using species-level data 
with the R package microbiome.25 We calculated the 
dissimilarity matrix (β diversity) and principal coordi-
nates using Bray-Curtis dissimilarity on compositional 
microbial species-level abundance using R packages 
Phyloseq26 and Vegan.27 The α diversity is a measure 
of within-sample diversity (eg, number of microbial 
species observed or number of questions needed on 
average to identify random microbe within sample), 
and the β diversity is a measure of between-sample 
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diversity (eg, euclidean distance, where each axis 
represents single species or ratio of number of spe-
cies shared and number of species in total). We ana-
lyzed the associations between β diversity and BP 
variables using permutational multivariate ANOVA 
with 999 permutations. We studied common micro-
bial genera (prevalent in at least 1% of sample popu-
lation with a relative abundance >0.1%) using DESeq2 
with the Benjamini-Hochberg correction.28,29 We ana-
lyzed associations of the genera with (1) BP indexes 
and (2) 24-hour urinary sodium excretion. We further 
studied the association between Lactobacillus and 
BP in subgroups by sex and antihypertensive medi-
cation. We performed more focused analysis for the 
detected Lactobacillus species, replicating the previ-
ous 2 steps. We log(x+1) transformed the KO groups. 
We used fully adjusted linear regression models to 
estimate the associations between KO groups and 
systolic BP. We visualized separately the associa-
tions between KO groups and systolic BP using the 
FuncTree package.30 For the module, pathway, and 
biological process layers, we used node sizes that 
corresponded to the average inverse P value of all 
KO groups that could be assigned to that node. The 
source code for the analyses is openly available at 
10.5281/zenodo.3622730.31 We used R32 version 
3.6.0 for all statistical analyses.
RESULTS
The characteristics of the main study sample and 
the 24-hour urinary sodium subsample are reported 
in Table. A small, but statistically significant, differ-
ence between the 2 samples was observed for age 
(P<0.001), diastolic BP (P=0.001), pulse pressure 
(P<0.001), heavy exercise (P=0.011), β-blocker use 
(P=0.046), and renin-angiotensin system blocker use 
(P=0.030). We observed 134 Lactobacillus species 
(Table S1) and 91 common microbial genera (4.7% of 
all available genera; Table S2).
In models adjusted for age and sex (Figure  1, 
Table  S3), an SD increase in microbiota α diver-
sity was inversely associated with systolic BP (effect 
size, −0.54 mm Hg; 95% CI, −0.96 to −0.12 mm Hg; 
P=0.012), diastolic BP (effect size, −0.31 mm Hg; 95% 
CI, −0.56 to −0.06 mm  Hg; P=0.016), mean arterial 
pressure (effect size, −0.39 mm Hg; 95% CI, −0.66 to 
−0.12 mm Hg; P=0.005), and hypertension (odds ratio, 
0.91; 95% CI, 0.86–0.96; P<0.001). However, α diver-
sity was not related to any BP variable in the multivari-
able-adjusted models (Figure 1, Table S3).
In the age- and sex-adjusted models, all BP 
indexes were significantly associated with β di-
versity (P≤0.038 for all; Figure 1, Table S4). The co-
efficients of determination between β diversity and 
Table. Characteristics of the Study Sample
Characteristics All Urinary Sodium Subsample P Value
No. 6953 829
Age, mean (SD), y 49.2 (12.88) 47.2 (10.94) <0.001
Women, N (%) 3819 (54.9) 460 (55.5) 0.720
BMI, mean (SD), kg/m2 27.0 (4.66) 26.7 (4.54) 0.117
Systolic BP, mean (SD), mm Hg 135.6 (20.20) 134.6 (18.65) 0.113
Diastolic BP, mean (SD), mm Hg 79.1 (11.23) 80.3 (11.12) 0.001
Pulse pressure, mean (SD), mm Hg 56.5 (16.39) 54.4 (14.16) <0.001
Arterial pressure, mean (SD), mm Hg 97.9 (12.67) 98.4 (12.40) 0.263
Hypertension, N (%) 3291 (47.3) 378 (45.6) 0.283
Current smoker, N (%) 1637 (23.5) 210 (25.3) 0.189
Diabetes mellitus, N (%) 390 (5.6) 36 (4.3) 0.081
Exercise, N (%)
Light 1466 (21.1) 167 (20.1) 0.545
Moderate 3922 (56.4) 445 (53.7) 0.109
Heavy 1565 (22.5) 217 (26.2) 0.011
Antihypertensive medication, N (%) 1253 (18.0) 122 (14.7)
Diuretics 232 (3.3) 20 (2.4) 0.145
β Blockers 714 (10.3) 68 (8.2) 0.046
Calcium channel blockers 293 (4.2) 32 (3.9) 0.670
RAS blockers 569 (8.2) 51 (6.2) 0.030
Continuous variables are presented as mean (SD), and categorical values are presented as count (percentage). Characteristics between individuals who 
were and were not included in the urinary sodium subsample were compared using the 2-sample T test and the χ2 test of equality of means. BP indicates blood 
pressure; BMI, body mass index; and RAS, renin-angiotensin system.
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BP variables varied between 0.02% and 0.06%. In 
multivariable-adjusted models, only diastolic BP 
(R2=0.02%; P=0.032) was significantly related to 
β diversity (Figure 1, Table S4). The first 3 principal 
coordinate axes explained 31.3% of the variation in 
bacterial abundances, but visual inspection did not 
reveal clustering of hypertensive and normotensive 
individuals (Figure 2).
We then studied the associations between ge-
nus-level abundances and BP indexes. We observed 
122 significant associations between 45 distinct mi-
crobial genera and BP indexes with false discovery 
Figure 1. Associations between blood pressure (BP) variables and microbial diversity.
The blue heat maps on the left express the change in BP variables per 1-SD increase in α diversity (Shannon 
index); log odds are reported for hypertension. The bar plots on the right represent the proportion of 
variability (R2) in β diversity (Bray-Curtis distance) explained by BP indexes. Multivariable-adjusted model 
is adjusted for age, sex, body mass index, smoking, exercise, diuretics, β blockers, calcium channel 
blockers, and renin-angiotensin system blockers. Significant results are marked with asterisk (P<0.05). α 
indicates effect size for α diversity; and MAP, mean arterial pressure.
Figure 2. Principal coordinate analysis (PCoA) for species-level bacterial abundances (Bray-
Curtis distance). 
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rate–corrected P<0.05 (Figure  3, Table  S5). These 
associations are shown in subgroups by sex and an-
tihypertensive medication use in Figures  S1 and S2. 
The results differed by subgroup for several species. 
Of all covariates, inclusion of body mass index in the 
age- and sex-adjusted model resulted in most of the 
reduction (from 39 to 23; 59%) in the number of sig-
nificant genera-hypertension associations. The as-
sociation between the Lactobacillus genus and BP 
indexes was nonsignificant, but species-level analyses 
revealed 41 significant associations for 19 (14.0%) dis-
tinct Lactobacillus species with false discovery rate–
corrected P<0.05. Of these associations, 12 were 
positive and 29 were negative (Figure  3, Table  S6). 
We observed 481 KO groups associated with systolic 
BP (false discovery rate–corrected P<0.05; Table S7). 
Internal node calculation revealed that several of the 
most prominent pathways were related to lipid metab-
olism, gluconeogenesis, and xenobiotic metabolism 
(Figure S3).
Finally, we performed a more focused analysis on 
the association between genus- and species-level 
Lactobacillus abundances and sodium intake in the 
subsample of participants with 24-hour urinary so-
dium excretion (mean, 142.3±62.9  mmol) data avail-
able. Lactobacillus prevalence was 15.5% at the 
detection limit of 0.1% relative abundance in this 
subsample. Lactobacillus genus was not associated 
with 24-hour urinary sodium excretion (false discov-
ery rate–corrected P=0.984; Figure 4). At the species 
level (Figure 4), Lactobacillus paracasei demonstrated 
Figure 3. Associations for common microbial genera and 
Lactobacillus species with blood pressure (BP) indexes.
We observed 45 distinct microbial genera and 19 Lactobacillus 
species that were significantly associated with BP indexes using 
DESeq2 (P<0.05 for all). The heat map expresses the fold change 
associated with BP indexes in base 2 logarithm ratios of microbial 
abundances. For hypertension, the range signifies a change of 
microbial abundance from 0.5 (blue) to 2 (red) times the bacterial 
abundance in normotensive participants. For continuous 
variables, the fold change is expressed per 1-SD change in 
BP variable. The models are adjusted for age, sex, body mass 
index, smoking, exercise, diuretics, β blockers, calcium channel 
blockers, and renin-angiotensin system blockers. Association 
with bacterial plasmid is denoted using asterisk. MAP indicates 
mean arterial pressure.
Figure 4. Lactobacillus abundance in groups by 24-hour 
urinary sodium excretion.
We observed significant association between 24-hour urinary 
sodium excretion and two Lactobacillus species with false 
discovery rate–corrected P<0.05 while the genus-level 
association remained insignificant. For Lactobacillus paracasei 
(log2 fold change, −0.018±0.002; P<0.001), the 24-hour 
urinary sodium excretion levels were as follows: quartile (Q) 1, 
205.4±68.5 mmol; Q2, 143.0±43.8 mmol; Q3, 123.9±41.1 mmol; 
and Q4, 96.6±33.7  mmol. For Lactobacillus salivarius (log2 
fold change, 0.007±0.002; P=0.004), the 24-hour urinary 
sodium excretion levels were as follows: Q1, 132.7±60.3 mmol; 
Q2, 142.3±63.3  mmol; Q3, 144.0±58.3  mmol; and Q4, 
150.1±68.6 mmol. We visualize the associations using quartiles 
of DESeq2-fitted abundances against 24-hour urinary sodium.
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a strong, negative association with (log2 fold change, 
−0.018±0.002; P<0.001) urinary sodium excretion. 
Lactobacillus salivarius was positively (log2 fold change, 
0.007±0.002; P=0.004) associated with urinary sodium 
excretion.
DISCUSSION
We investigated the relation between the gut metage-
nome and objectively measured BP in a large, repre-
sentative population cohort while adjusting for relevant 
confounding factors. In age- and sex-adjusted models, 
we observed strong associations between overall gut 
taxonomic composition and BP. However, these as-
sociations were weaker in multivariable-adjusted mod-
els. We observed significant associations between 45 
distinct microbial genera and BP indexes, of which 27 
belong to the phylum Firmicutes. Interestingly, certain 
Lactobacillus species demonstrated strong associa-
tions with both BP indexes and 24-hour urinary so-
dium excretion. Our functional analysis suggests that 
microbiome-driven processes associated with lipid 
metabolism, gluconeogenesis, and xenobiotic me-
tabolism may be associated with BP. However, experi-
mental designs with deep microbiome sequencing are 
needed for more detailed information on the causal/
functional mechanisms and, ultimately, the clinical sig-
nificance of our findings.
Several prior animal studies have suggested an as-
sociation between intestinal dysbiosis and hyperten-
sion.4 A lower gut microbiota α diversity was reported 
among hypertensive cases in a small case-control 
study with a study sample of 11 rats and 17 human 
patients.5 In another experimental study by Adnan et 
al,6 6 normotensive rats were gavaged with microbiota 
from hypertensive rats, which led to increases in the 
Firmicutes/Bacteroides ratio and systolic BP. Finally, 
Durgan et al33 suggested that a causal relationship 
between gut microbial dysbiosis and obstructive sleep 
apnea–induced hypertension could exist in groups of 
6 to 9 rats allocated to high-fat and normal chow diet. 
These early animal studies have suggested that gut 
dysbiosis and hypertension could be causally related, 
offering a basis for large-scale epidemiological studies 
in humans.
Two previous cohort studies have assessed the 
association between 16S rRNA-sequenced gut mi-
crobiota and hypertension in humans. Jackson et 
al13 studied the link between gut microbiota markers 
and self-reported common diseases in a sample of 
2737 TwinsUK study participants. However, no asso-
ciations were observed between 68 various micro-
biota markers and self-declared hypertension after 
correcting for multiple testing. As previously noted,15 
the prevalence of self-reported hypertension (27.6%) 
in TwinsUK was lower than expected and, therefore, 
the lack of objective BP measurements could ex-
plain these nonsignificant results. In another study 
by Sun et al,14 the authors examined the association 
between gut microbiota and objectively measured 
BP in 529 CARDIA study participants. This study 
reported a negative association between gut mi-
crobial α diversity and systolic BP. The authors also 
observed a single significant genus-level association 
between systolic BP and Robinsoniella, which was 
not included in common microbial genera (preva-
lence, ≥1%; abundance, ≥0.1%) used in this study. 
Our study builds on these earlier efforts through 
the use of shotgun metagenomic sequencing and a 
large, representative study sample with detailed drug 
purchase data, standardized BP measurements, and 
adequate statistical power. Although the multivari-
able-adjusted associations between overall gut tax-
onomic composition and BP observed in our study 
were small, we demonstrate mainly positive associa-
tions between 45 microbial genera and BP indexes. 
A total of 27 of these 45 genera belong to the phy-
lum Firmicutes, highlighting the previously observed 
potentially harmful links of increased Firmicutes with 
hypertension, obesity, diabetes mellitus, and chronic 
kidney disease.5,34
In a previous publication, Wilck et al8 studied the 
effects of high dietary salt intake on gut-immune 
axis through induction of interleukin-17A–producing 
T-helper 17 cells, which can also contribute to hy-
pertension. The authors reported that Lactobacillus 
murinus was depleted by high dietary salt in mouse 
models, whereas L murinus treatment prevented 
salt-sensitive hypertension by modulating T-helper 
17 cells. In the same study, markedly increased 
salt intake also led to reduced Lactobacillus spe-
cies abundance, increased T-helper 17 cell levels, 
and increased BP in a small sample of 12 men and 
women. In line with the results by Wilck et al,8 we 
observed mainly negative, but also positive, associa-
tions between Lactobacillus species and BP indexes. 
Although the Lactobacillus genus was not associ-
ated with 24-hour urinary sodium excretion, we ob-
served a strong association between an increased L 
paracasei abundance and decreased urinary sodium 
excretion (P<0.001; Figure 4). A positive association 
between L salivarius and sodium excretion was also 
observed (P=0.004). The directions of the effects 
for both Lactobacillus species were consistent in 
models for BP and dietary sodium. However, the 
Lactobacillus-related results were somewhat differ-
ent in subgroups by sex and antihypertensive med-
ication use. In particular, the association between L 
paracasei and BP was stronger in women. The asso-
ciation between L paracasei and BP was observed in 
users and nonusers of antihypertensive medications. 
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The underlying mechanisms of these associations 
require further study, but the probiotic supplemen-
tation with L paracasei has been previously shown 
to reduce interleukin-17 levels in acutely ill patients 
and Lactobacillus casei group on the whole to induce 
potential weight loss.35,36
Although our study has several advantages, our re-
sults must be interpreted in the context of their limita-
tions. First, although fecal sampling is a noninvasive 
and feasible method for assessing microbiota, it is only 
a proxy for the gut microbiota. In particular, the stable 
microbial niche in mucosal layer of the gastrointestinal 
tract could account for major physiological effects with 
minor contribution to stool sampling.37 Second, the rel-
atively long storage time of the samples (15 years at 
−20°C) could lead to some deterioration of the sam-
ples. However, the taxonomic composition of our sam-
ples was similar to what has been previously observed 
in larger cohort studies.19 Third, metagenomics is a 
novel field with reported limitations (eg, those related 
to sequencing and labeling DNA in stool samples).38 
Fourth, despite 24-hour urine collection being a more 
accurate method for estimating sodium intake than 
spot urine samples, it remains a cross-sectional snap-
shot of dietary habits.39 Fifth, the hypertensive partic-
ipants of our study may have received instructions to 
reduce their sodium intake, leading to weaker or re-
verse causation.
CONCLUSIONS
This study is by far the largest to examine the as-
sociation between human gut microbiota and ob-
jectively measured BP. Although the associations 
between overall gut taxonomic composition and BP 
are weak, individuals with hypertension demonstrate 
changes in several microbiota genera, with most of 
these genera belonging to the Firmicutes phylum. 
Interestingly, we also demonstrate strong negative 
associations of certain Lactobacillus species with 
both dietary sodium intake and BP (Figures  3 and 
4). This finding provides additional population-level 
evidence to those from experimental studies dem-
onstrating that distinct Lactobacillus species are de-
pleted by high dietary salt, whereas treatment with 
these same species might prevent salt-sensitive 
hypertension.8 Our research needs to be expanded 
(1) by estimating the effect of the reported associa-
tions for public health, (2) by determining the func-
tional role of gut microbiota by combining taxonomic 
profiling with simultaneous determination of the gut 
and plasma metabolome, and (3) by conducting ad-
ditional studies that directly manipulate Lactobacillus 
species levels in the gut to establish the causal rela-
tion between these species and hypertension. The 
observed associations between the gut microbial 
composition and hypertension offer novel insights on 
the potential mechanisms through which diet affects 
the gut microbiome and BP. In addition, our results 
raise hypotheses on how the microbiome could be 
manipulated to improve hypertension control.
ARTICLE INFORMATION
Received March 18, 2020; accepted June 22, 2020.
Affiliations
From the Department of Medicine (J.P., A.S., T.J.N.), Department of Public 
Health Solutions Finnish Institute for Health and Welfare, Helsinki, Finland 
(J.P., A.S.H., E.V., T.L., P.J., V.S., T.J.N.); Department of Future Technologies 
University of Turku, Finland (A.S., L.L.);  Institute for Molecular Medicine 
Finland (FIMM) and Helsinki Institute of Life Science (HiLIFE), Helsinki, Finland 
(A.S.H.); Division of Cardiology Brigham and Women’s Hospital, Boston, 
MA (S.C.);  Smidt Heart Institute, Los Angeles, CA (S.C.); Cambridge Baker 
Systems Genomics Initiative Baker Heart and Diabetes Institute, Melbourne, 
Australia (M.I.); Cambridge Baker Systems Genomics Initiative, Department 
of Public Health and Primary Care University of Cambridge, United Kingdom 
(M.I.); Departments of Medicine and Pharmacology (M.J.) and Department of 
Pediatrics (R.A.S., K.S., C.B., G.C.H., J.G.S., R.K.), University of California, 
San Diego, CA; Institute of Public Health and Clinical Nutrition University 
of Eastern Finland, Kuopio, Finland (T.L.); and Joint Municipal Authority for 
North Karelia Social and Health Services, Joensuu, Finland (T.L.).
Acknowledgments
We thank the participants and staff of the FINRISK 2002 study. We thank 
Illumina, Inc, and Janssen Pharmaceutica for their support of the Center for 
Microbiome Innovation at University of California, San Diego. We thank Ville 
Laitinen for the assistance with functional analyses used in this article.
Author contributions: Drs Salomaa, Knight, Lahti, and Niiranen de-
signed the work; Drs Havulinna, Jain, Salido, Sanders, Brennan, Humphrey, 
Vartiainen, Laatikainen, Jousilahti, and Salomaa acquired the data; Drs 
Palmu, Salosensaari, Sanders, Lahti, and Niiranen analyzed the data; and 
Drs Cheng, Inouye, Jain, Jousilahti, Salomaa, Knight, Lahti, and Niiranen 
supervised the work. All authors wrote the article and gave final approval of 
the version to be published.
Sources of Funding
Dr Niiranen was funded by Emil Aaltonen Foundation, Paavo Nurmi 
Foundation, Finnish Medical Foundation, and Academy of Finland, grant 
321351. Dr Lahti was funded by Academy of Finland, grants 295741 
and 307127. Dr Salomaa was supported by the Finnish Foundation for 
Cardiovascular Research. Dr Havulinna was supported by Academy of 
Finland, grant 321356. Dr Jain was supported in part by grants from the 
National Institutes of Health (NIH), including NIH S10OD020025 and 
R01ES027595. Dr Cheng was supported by NIH grants R01-HL134168, 
R01-HL131532, R01-HL143227, and R01-HL142983. The funding bodies had 
no role in the design of the study, in collection, analysis, and interpretation of 
data, and in writing the article.
Disclosures
Dr Salomaa has received honoraria from Novo Nordisk and Sanofi for con-
sultations. He also has ongoing research collaboration with Bayer Ltd (all 
unrelated to the present study). The remaining authors have no disclosures 
to report.
Supplementary Materials
Tables S1–S7
Figures S1–S3
REFERENCES
 1. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen 
D, et al. A metagenome-wide association study of gut microbiota in type 
2 diabetes. Nature. 2012;490:55–60.
D
ow
nloaded from
 http://ahajournals.org by on October 21, 2020
J Am Heart Assoc. 2020;9:e016641. DOI: 10.1161/JAHA.120.016641 9
Palmu et al Blood Pressure and Microbiota
 2. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein 
AE, Britt EB, Fu X, Chung Y-M, et al. Gut flora metabolism of phospha-
tidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.
 3. O’Keefe SJD, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, Posma 
JM, Kinross J, Wahl E, Ruder E, et al. Fat, fibre and cancer risk in African 
Americans and rural Africans. Nat Commun. 2015;6:6342.
 4. Richards EM, Pepine CJ, Raizada MK, Kim S. The gut, its microbiome, 
and hypertension. Curr Hypertens Rep. 2017;19:36.
 5. Yang T, Santisteban MM, Vermali R, Li E, Ahmari N, Carvajal JM, Zadeh 
M, Gong M, Qi Y, Zubcevic J, et al. Gut dysbiosis is linked to hyperten-
sion. Hypertension. 2015;65:1331–1340.
 6. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM, 
Durgan DJ. Alterations in the gut microbiota can elicit hypertension in 
rats. Physiol Genomics. 2016;49:96–104.
 7. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, 
Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic 
syndrome and altered gut microbiota in mice lacking toll-like receptor 5. 
Science. 2010;328:228–231.
 8. Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus 
H, Haase S, Mähler A, Balogh A, Markó L, et al. Salt-responsive gut com-
mensal modulates T H 17 axis and disease. Nature. 2017;551:585–589.
 9. McDonald D, Hyde E, Debelius JW, Morton JT, Gonzalez A, Ackermann 
G, Aksenov AA, Behsaz B, Brennan C, Chen Y, et al. American gut: 
an open platform for citizen science microbiome research. mSystems. 
2018;3:e00031-18. DOI: 10.1128/mSyst ems.00031 -18.
 10. Jäckel S, Kiouptsi K, Lillich M, Hendrikx T, Khandagale A, Kollar B, 
Hörmann N, Reiss C, Subramaniam S, Wilms E, et al. Gut microbiota 
regulate hepatic von Willebrand factor synthesis and arterial thrombus 
formation via Toll-like receptor-2. Blood. 2017;130:542–553.
 11. Kiouptsi K, Jäckel S, Pontarollo G, Grill A, Kuijpers MJE, Wilms E, 
Weber C, Sommer F, Nagy M, Neideck C, et al. The microbiota pro-
motes arterial thrombosis in low-density lipoprotein receptor-deficient 
mice. mBio. 2019;10:e02298-19. DOI: 10.1128/mBio.02298 -19.
 12. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, 
Mehrabian M, et al. Gut microbial metabolite TMAO enhances platelet 
hyperreactivity and thrombosis risk. Cell. 2016;165:111–124.
 13. Jackson MA, Verdi S, Maxan M-E, Shin CM, Zierer J, Bowyer RCE, 
Martin T, Williams FMK, Menni C, Bell JT, et al. Gut microbiota associa-
tions with common diseases and prescription medications in a popula-
tion-based cohort. Nat Commun. 2018;9:1–8.
 14. Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR, Shikany 
JM, Lloyd-Jones DM, Launer LJ, Fodor AA, et al. Gut microbiota 
composition and blood pressure: the CARDIA study. Hypertension. 
2019;73:998–1006.
 15. Jama H, Kaye DM, Marques FZ. Population-based gut microbiome as-
sociations with hypertension. Circ Res. 2018;123:1185–1187.
 16. Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, 
Laatikainen T, Mannisto S, Salomaa V, Sundvall J, Puska P. Forty-year 
trends in cardiovascular risk factors in Finland. Eur J Public Health. 
2015;25:539–546.
 17. Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, 
Salomaa V, Laaksonen R. Circulating ceramides predict cardiovascular 
outcomes in the population-based FINRISK 2002 cohort. Arterioscler 
Thromb Vasc Biol. 2016;36:2424–2430.
 18. Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H, Tuomilehto J. 
Sodium in the Finnish diet: 20-year trends in urinary sodium excretion 
among the adult population. Eur J Clin Nutr. 2006;60:965–970.
 19. Salosensaari A, Laitinen V, Havulinna AS, Meric G, Cheng S, Perola M, 
Valsta L, Alfthan G, Inouye M, Watrous JD, et al. Taxonomic signatures 
of long-term mortality risk in human gut microbiota. medRxiv. 2020. 
DOI: 2019.12.30.19015842
 20. Glenn TC, Nilsen RA, Kieran TJ, Sanders JG, Bayona-Vásquez NJ, 
Finger JW, Pierson TW, Bentley KE, Hoffberg SL, Louha S, et al. 
Adapterama I: universal stubs and primers for 384 unique dual-indexed 
or 147,456 combinatorially-indexed Illumina libraries (iTru & iNext). 
PeerJ. 2019;7:e7755.
 21. Hillmann B, Al-Ghalith GA, Shields-Cutler RR, Zhu Q, Gohl DM, 
Beckman KB, Knight R, Knights D. Evaluating the information content 
of shallow shotgun metagenomics. mSystems. 2018;3:e00069-18.
 22. O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, 
Rajput B, Robbertse B, Smith-White B, Ako-Adjei D, et al. Reference 
sequence (RefSeq) database at NCBI: current status, taxonomic ex-
pansion, and functional annotation. Nucleic Acids Res. 2016;44: 
D733–D745.
 23. Statistics on reimbursements for prescription medicines. The Social 
Insurance Institution of Finland (Kela). https://www.kela.fi/web/en/492. 
Accessed August 5, 2019.
 24. ATC Structure and Principles. WHO Collaborating Centre for Drug 
Statistics Methodology. https://www.whocc.no/atc/struc ture_and_
princ iples/. Accessed August 5, 2019.
 25. Lahti L, Shetty S. Tools for microbiome analysis in R: version 1.6.0. 2017. 
Available at: http://micro biome.github.com/micro biome. Accessed May 
2, 2019.
 26. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible in-
teractive analysis and graphics of microbiome census data. PLoS One. 
2013;8:e61217.
 27. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn 
D, Minchin PR, O’Hara RB, Simpson GL, Solymos P, et al. The Vegan 
package: version 2.5.6. 2007. https://CRAN.R-proje ct.org/packa 
ge=vegan.Accessed April 24, 2019.
 28. Love MI, Huber W, Anders S. Moderated estimation of fold change 
and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15: 
550.
 29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a prac-
tical and powerful approach to multiple testing. J R Stat Soc Ser B 
Methodol. 1995;57:289–300.
 30. Uchiyama T, Irie M, Mori H, Kurokawa K, Yamada T. FuncTree: func-
tional analysis and visualization for large-scale omics data. PLoS One. 
2015;10:e0126967.
 31. Palmu J, Salosensaari A, Lahti L, Niiranen T. RRgutbiota: source code 
for the manuscript association between gut microbiota and blood pres-
sure in a population cohort of 6953 individuals: version 1.6. Zenodo; 
2020. DOI: 10.5281/zenodo.3622730. Accessed June 24, 2020.
 32. R Core Team. R: A Language and Environment for Statistical Computing: 
Version 3.6.0. R Foundation for Statistical Computing; 2017. https://ww-
w.R-proje ct.org/. Accessed May 2, 2019.
 33. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, 
Hollister EB, Bryan RM. Role of the gut microbiome in obstructive sleep 
apnea-induced hypertension. Hypertension. 2016;67:469–474.
 34. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health 
and disease. Circ Res. 2017;120:1183–1196.
 35. Angurana SK, Bansal A, Singhi S, Aggarwal R, Jayashree M, Salaria M, 
Mangat NK. Evaluation of effect of probiotics on cytokine levels in crit-
ically ill children with severe sepsis: a double-blind, placebo-controlled 
trial. Crit Care Med. 2018;46:1656–1664.
 36. Hill D, Sugrue I, Tobin C, Hill C, Stanton C, Ross RP. The Lactobacillus 
casei group: history and health related applications. Front Microbiol. 
2018;9:2107. DOI: 10.3389/fmicb.2018.02107.
 37. Claesson MJ, Clooney AG, O’Toole PW. A clinician’s guide to microbi-
ome analysis. Nat Rev Gastroenterol Hepatol. 2017;14:585–595.
 38. Thomas AM, Segata N. Multiple levels of the unknown in microbiome 
research. BMC Biol. 2019;17:48.
 39. Rakova N, Kitada K, Lerchl K, Dahlmann A, Birukov A, Daub S, Kopp 
C, Pedchenko T, Zhang Y, Beck L, et al. Increased salt consumption 
induces body water conservation and decreases fluid intake. J Clin 
Invest. 2017;127:1932–1943.
D
ow
nloaded from
 http://ahajournals.org by on October 21, 2020
  
 
 
SUPPLEMENTAL MATERIAL 
 
  
D
ow
nloaded from
 http://ahajournals.org by on October 21, 2020
Table S1. Lactobacillus species (N=134). 
 
Ace–Dex Dio–Kim Kim–Pla Pob–Xia 
L. acetotolerans L. diolivorans L. kimchiensis L. pobuzihii 
L. acidifarinae L. equi L. koreensis L. pontis 
L. acidipiscis L. equicursoris L. kullabergensis L. psittaci 
L. acidophilus L. equigenerosi L. kunkeei L. rapi 
L. agilis L. fabifermentans L. lindneri L. rennini 
L. algidus L. farciminis L. lindneri* L. reuteri 
L. alimentarius L. farraginis L. malefermentans L. rhamnosus 
L. amylolyticus L. fermentum L. manihotivorans L. rossiae 
L. amylotrophicus L. floricola L. mellifer L. ruminis 
L. amylovorus L. florum L. mellifer* L. saerimneri 
L. amylovorus* L. fructivorans L. mellis L. sakei 
L. animalis L. frumenti L. mindensis L. salivarius 
L. antri L. fuchuensis L. mucosae L. salivarius* 
L. apinorum L. gasseri L. mucosae* L. sanfranciscensis 
L. apis L. gastricus L. nagelii L. sanfranciscensis* 
L. apis* L. ghanensis L. nasuensis L. saniviri 
L. aquaticus L. gigeriorum L. nodensis L. satsumensis 
L. aviarius L. ginsenosidimutans L. odoratitofui L. secaliphilus 
L. bifermentans L. graminis L. oeni L. selangorensis 
L. brantae L. hamsteri L. oligofermentans L. senioris 
L. brevis L. harbinensis L. oryzae L. sharpeae 
L. brevis* L. hayakitensis L. ozensis L. shenzhenensis 
L. buchneri L. heilongjiangensis L. panis L. siliginis 
L. buchneri* L. helveticus L. pantheris L. similis 
L. cacaonum L. herbarum L. parabrevis L. spicheri 
L. camelliae L. hilgardii L. parabuchneri L. sucicola 
L. capillatus L. hokkaidonensis L. parabuchneri* L. suebicus 
L. ceti L. hokkaidonensis* L. paracasei L. thailandensis 
L. coleohominis L. hominis L. paracasei* L. tucceti 
L. composti L. hordei L. paracollinoides L. uvarum 
L. concavus L. iners L. paracollinoides* L. vaccinostercus 
L. coryniformis L. ingluviei L. parafarraginis L. vaginalis 
L. crispatus L. intestinalis L. paralimentarius L. versmoldensis 
L. crustorum L. jensenii L. pasteurii L. vini 
L. crustorum* L. kalixensis L. paucivorans L. wasatchensis 
L. curieae L. kefiranofaciens L. perolens L. xiangfangensis 
L. delbrueckii L. kefiranofaciens* L. plantarum  
L. dextrinicus L. kimchicus L. plantarum*  
Bacterial plasmids are denoted with an asterisk. 
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Table S2. Common microbial genera (N=91, prevalence ≥1%, abundance 
≥0.1%). 
Ace–Dia Die–Lac Mar–Vei 
Acetivibrio Dielma Marvinbryantia 
Acidaminococcus Dorea Megamonas 
Actinomyces Eggerthella Megasphaera 
Adlercreutzia Eisenbergiella Methanobrevibacter 
Akkermansia Enorma Methanomassiliicoccus 
Alistipes Enterobacter Mitsuokella 
Alloprevotella Enterococcus Odoribacter 
Anaerostipes Erysipelatoclostridium Oscillibacter 
Anaerotruncus Escherichia Parabacteroides 
Bacteroides Escherichia* Paraprevotella 
Bacteroides* Eubacterium Parasutterella 
Barnesiella Eubacterium* Phascolarctobacterium 
Bifidobacterium Faecalibacterium Phocea 
Bilophila Faecalicatena Porphyromonas 
Bittarella Faecalicoccus Prevotella 
Blautia Faecalitalea Roseburia 
Butyricicoccus Fournierella Ruminiclostridium 
Butyricimonas Gordonibacter Ruminococcus 
Butyrivibrio Haemophilus Ruthenibacterium 
Catenibacterium Halapricum Sanguibacteroides 
Caudovirales Holdemanella Sellimonas 
Cellulomonas Holdemania Senegalimassilia 
Citrobacter Hungatella Shigella 
Clostridioides Intestinibacter Solobacterium 
Clostridium Johnsonella Streptococcus 
Collinsella Klebsiella Subdoligranulum 
Coprobacillus Klebsiella* Sutterella 
Coprobacter Kluyvera Tannerella 
Coprococcus Lachnoanaerobaculum Turicibacter 
Dakarella Lachnoclostridium Tyzzerella 
Desulfovibrio Lactobacillus Veillonella 
Dialister Lactococcus  
Bacterial plasmids are denoted with an asterisk.  
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Table S3. Associations between blood pressure indices and microbial alpha 
diversity. 
 Age- and sex-adjusted model Multivariable-adjusted model 
 β (95%-CI) p β (95%-CI) p 
Systolic BP -0.54 (-0.96 to -0.12)  0.012  -0.20 (-0.62 to 0.21)  0.334  
Diastolic BP -0.31 (-0.56 to -0.06)  0.016  -0.10 (-0.35 to 0.14)  0.404  
Mean arterial pressure -0.39 (-0.66 to -0.12)  0.005  -0.14 (-0.40 to 0.12)  0.304  
Pulse pressure -0.23 (-0.59 to 0.13)  0.203  -0.10 (-0.46 to 0.26)  0.580  
Hypertension 0.91 (0.86 to 0.96)  <0.001  0.98 (0.92 to 1.04)  0.498  
Multivariable-adjusted model is adjusted for age, sex, BMI, smoking, exercise, 
diuretics, beta blockers, calcium channel blockers, and renin–angiotensin system 
blockers. BP, blood pressure. 
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Table S4. Associations between blood pressure indices and microbial beta 
diversity. 
 Age- and sex adjusted model Multivariable adjusted model 
 R2 p R2 p 
Systolic BP 0.046%  0.001  0.018%  0.195  
Diastolic BP 0.053%  0.001  0.024%  0.032  
Mean arterial pressure 0.058%  0.001  0.020%  0.126  
Pulse pressure 0.024%  0.038  0.020%  0.086  
Hypertension 0.046%  0.002  0.015%  0.376  
Analysis of variance for beta diversity was calculated using 999 permutations. 
Multivariable-adjusted model is adjusted for age, sex, BMI, smoking, exercise, 
diuretics, beta blockers, calcium channel blockers, and renin–angiotensin system 
blockers. BP, blood pressure. 
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Table S5. Associations between gut microbial genera and blood pressure indices. 
 Systolic BP Diastolic BP Pulse pressure Mean arterial pressure Hypertension 
 Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p 
Acidaminococcus   0.32±0.04 <0.001 -0.29±0.04 <0.001 0.20±0.04 <0.001   
Actinomyces   0.04±0.01 0.011 -0.03±0.01 0.045   0.10±0.03 0.008 
Adlercreutzia -0.07±0.02 0.008 -0.06±0.02 0.042   -0.07±0.02 0.006   
Alloprevotella         -0.12±0.04 0.006 
Anaerostipes 0.06±0.02 0.015       0.16±0.04 <0.001 
Anaerotruncus -0.05±0.01 <0.001   -0.05±0.01 <0.001 -0.03±0.01 0.010 -0.06±0.02 0.037 
Bacteroides   0.05±0.02 0.027   0.05±0.02 0.022   
Bacteroides*   0.17±0.04 <0.001   0.16±0.04 <0.001   
Blautia 0.04±0.01 0.015 0.03±0.01 0.038   0.04±0.01 0.008 0.11±0.03 <0.001 
Cellulomonas 0.10±0.03 0.016   0.15±0.03 <0.001     
Citrobacter   -0.43±0.04 <0.001 0.17±0.04 <0.001 -0.33±0.04 <0.001 0.35±0.10 0.002 
Clostridioides   0.13±0.02 <0.001 -0.12±0.02 <0.001 0.09±0.02 <0.001   
Collinsella   0.13±0.02 <0.001   0.12±0.02 <0.001 0.19±0.05 0.002 
Coprobacillus -0.12±0.02 <0.001 -0.06±0.02 0.006 -0.10±0.02 <0.001 -0.10±0.02 <0.001 -0.20±0.04 <0.001 
Coprococcus 0.05±0.01 0.004   0.05±0.01 0.004   0.10±0.03 0.012 
Desulfovibrio 0.13±0.03 <0.001 0.16±0.03 <0.001   0.17±0.03 <0.001   
Dialister 0.10±0.04 0.039   0.13±0.04 0.002     
Dielma 0.23±0.03 <0.001 0.14±0.03 <0.001 0.15±0.03 <0.001 0.22±0.03 <0.001 0.28±0.07 0.001 
Dorea         0.08±0.03 0.030 
Eisenbergiella   0.16±0.03 <0.001   0.13±0.03 <0.001 0.17±0.06 0.018 
Enorma         0.11±0.04 0.050 
Enterobacter 0.25±0.04 <0.001 -0.15±0.04 <0.001 0.32±0.04 <0.001   0.89±0.09 <0.001 
Erysipelatoclostridium   0.06±0.02 0.006   0.05±0.02 0.031 0.13±0.04 0.011 
Faecalicoccus -0.05±0.02 0.041   -0.06±0.02 0.003     
Faecalitalea         0.08±0.03 0.047 
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 Systolic BP Diastolic BP Pulse pressure Mean arterial pressure Hypertension 
 Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p 
Fournierella -0.02±0.01 0.022     -0.03±0.01 0.015 -0.07±0.02 0.002 
Holdemania 0.10±0.02 <0.001 0.10±0.02 <0.001   0.12±0.02 <0.001 0.20±0.04 <0.001 
Hungatella -0.09±0.02 <0.001   -0.09±0.02 <0.001 -0.06±0.02 0.006   
Intestinibacter         0.17±0.06 0.030 
Kluyvera   -0.26±0.04 <0.001 0.24±0.04 <0.001 -0.11±0.04 0.047 0.55±0.09 <0.001 
Lachnoclostridium   0.04±0.01 0.008 -0.04±0.01 0.005     
Lactococcus         0.18±0.07 0.047 
Megasphaera 0.19±0.03 <0.001   0.19±0.03 <0.001 0.14±0.03 <0.001 0.23±0.07 0.008 
Mitsuokella 0.15±0.04 0.001 -0.14±0.04 0.001 0.25±0.04 <0.001     
Paraprevotella 0.09±0.03 0.017   0.10±0.03 0.005     
Parasutterella   -0.10±0.04 0.030       
Phascolarctobacterium 0.10±0.03 0.011   0.08±0.03 0.042 0.08±0.03 0.038 0.22±0.07 0.007 
Prevotella   -0.09±0.03 0.048       
Ruthenibacterium 0.07±0.02 0.004   0.08±0.02 0.001   0.12±0.05 0.034 
Sanguibacteroides   0.08±0.02 0.005   0.08±0.02 0.006   
Sellimonas   -0.15±0.02 <0.001 0.09±0.02 <0.001 -0.10±0.02 <0.001   
Senegalimassilia         -0.18±0.05 0.003 
Solobacterium -0.08±0.02 0.001   -0.07±0.02 0.005 -0.06±0.02 0.014   
Sutterella 0.11±0.04 0.010 0.11±0.03 0.008   0.13±0.04 0.002   
Turicibacter 0.16±0.04 <0.001 0.13±0.03 <0.001 0.09±0.03 0.030 0.17±0.04 <0.001   
Tyzzerella   -0.04±0.01 0.033       
 
Models are adjusted for age, sex, BMI, smoking, exercise, diuretics, beta blockers, calcium channel blockers, and renin–
angiotensin system blockers. Association with bacterial plasmid is denoted using asterisk. BP, blood pressure. Log2FC, base 2 log 
of fold change.  
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Table S6. Associations between Lactobacillus species and blood pressure indices. 
 Systolic BP Diastolic BP Pulse pressure 
Mean arterial 
pressure 
Hypertension 
 Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p Log2FC±SE p 
L. agilis   -0.19±0.06 0.017   -0.20±0.06 0.013   
L. algidus         0.30±0.09 0.010 
L. amylotrophicus   -0.22±0.06 0.003       
L. aviarius -0.13±0.03 0.001   -0.09±0.03 0.043 -0.12±0.03 0.003   
L. equicursoris         -0.25±0.07 0.003 
L. farciminis -0.33±0.05 <0.001 -0.19±0.04 <0.001 -0.27±0.04 <0.001 -0.30±0.05 <0.001 -0.60±0.10 <0.001 
L. hominis -0.26±0.04 <0.001   -0.27±0.04 <0.001 -0.16±0.04 0.003 -0.42±0.09 <0.001 
L. iners -0.18±0.05 0.013 0.44±0.05 <0.001 -0.43±0.05 <0.001 0.17±0.05 0.02 -0.45±0.11 0.001 
L. jensenii     -0.16±0.05 0.011     
L. kalixensis 0.23±0.07 0.013     0.22±0.06 0.013   
L. kefiranofaciens 0.20±0.06 0.025         
L. kimchicus     -0.61±0.19 0.025 0.65±0.20 0.023   
L. parabuchneri         0.50±0.15 0.017 
L. paracasei -0.15±0.04 0.020 -0.23±0.04 <0.001   -0.23±0.04 <0.001   
L. pasteurii     -0.12±0.03 <0.001   -0.29±0.06 <0.001 
L. rhamnosus         0.65±0.12 <0.001 
L. ruminis   -0.32±0.04 <0.001   -0.26±0.04 <0.001 -0.49±0.08 <0.001 
L. sakei 0.15±0.04 0.009     0.13±0.04 0.038   
L. salivarius*     0.52±0.11 <0.001     
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Models are adjusted for age, sex, BMI, smoking, exercise, diuretics, beta blockers, calcium channel blockers, and renin–
angiotensin system blockers. Association with bacterial plasmid is denoted using asterisk. BP, blood pressure. Log2FC, base 2 log 
of fold change.
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Table S7. Associations between KO groups and systolic BP. 
KO-group  Definition  β (95%-CI) P  
K00169  pyruvate ferredoxin oxidoreductase alpha subunit  -0.04 (-0.06 to -0.02)  0.029  
K00170  pyruvate ferredoxin oxidoreductase beta subunit  -0.04 (-0.06 to -0.02)  0.029  
K00171  pyruvate ferredoxin oxidoreductase delta subunit  -0.04 (-0.06 to -0.02)  0.029  
K00172  pyruvate ferredoxin oxidoreductase gamma subunit  -0.04 (-0.06 to -0.02)  0.029  
K00402  methyl-coenzyme M reductase gamma subunit  -0.04 (-0.06 to -0.02)  0.029  
K00581  tetrahydromethanopterin S-methyltransferase subunit E  -0.04 (-0.06 to -0.02)  0.029  
K01854  UDP-galactopyranose mutase  -0.04 (-0.06 to -0.02)  0.029  
K02201  pantetheine-phosphate adenylyltransferase  -0.04 (-0.06 to -0.02)  0.029  
K02910  large subunit ribosomal protein L31e  -0.04 (-0.06 to -0.02)  0.029  
K02944  large subunit ribosomal protein LX  -0.04 (-0.06 to -0.02)  0.029  
K03049  DNA-directed RNA polymerase subunit E'  -0.04 (-0.06 to -0.02)  0.029  
K03105  signal recognition particle subunit SRP19  -0.04 (-0.06 to -0.02)  0.029  
K03136  transcription initiation factor TFIIE subunit alpha  -0.05 (-0.07 to -0.03)  0.029  
K03538  ribonuclease P protein subunit POP4  -0.04 (-0.06 to -0.02)  0.029  
K04801  replication factor C small subunit  -0.04 (-0.06 to -0.02)  0.029  
K07060  endoribonuclease Nob1  -0.04 (-0.06 to -0.02)  0.029  
K07133  uncharacterized protein  -0.04 (-0.06 to -0.02)  0.029  
K07143  UPF0148 protein  -0.04 (-0.06 to -0.02)  0.029  
K07333  archaeal flagellar protein FlaJ  -0.04 (-0.06 to -0.02)  0.029  
K07722  
CopG family transcriptional regulator, nickel-responsive 
regulator  -0.04 (-0.06 to -0.02)  0.029  
K07730  putative transcriptional regulator  -0.04 (-0.06 to -0.02)  0.029  
K07991  archaeal preflagellin peptidase FlaK  -0.04 (-0.06 to -0.02)  0.029  
K09713  uncharacterized protein  -0.05 (-0.07 to -0.02)  0.029  
K09738  uncharacterized protein  -0.04 (-0.06 to -0.02)  0.029  
K12960  5-methylthioadenosine/S-adenosylhomocysteine deaminase  -0.04 (-0.06 to -0.02)  0.029  
K13787  geranylgeranyl diphosphate synthase, type I  -0.04 (-0.06 to -0.02)  0.029  
K14100  energy-converting hydrogenase A subunit I  -0.04 (-0.06 to -0.02)  0.029  
K14104  energy-converting hydrogenase A subunit M  -0.04 (-0.06 to -0.02)  0.029  
K14561  U3 small nucleolar ribonucleoprotein protein IMP4  -0.05 (-0.07 to -0.03)  0.029  
K14654  
2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5'-
phosphate reductase  -0.05 (-0.07 to -0.02)  0.029  
K17104  phosphoglycerol geranylgeranyltransferase  -0.04 (-0.06 to -0.02)  0.029  
K18237  ribose 1,5-bisphosphate isomerase  -0.04 (-0.06 to -0.02)  0.029  
K04800  replication factor C large subunit  -0.04 (-0.06 to -0.02)  0.029  
K07739  elongator complex protein 3  -0.04 (-0.06 to -0.02)  0.029  
K07142  
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine 
diphosphokinase  -0.04 (-0.06 to -0.02)  0.030  
K00180  indolepyruvate ferredoxin oxidoreductase, beta subunit  -0.04 (-0.06 to -0.02)  0.030  
K01251  adenosylhomocysteinase  -0.04 (-0.06 to -0.02)  0.030  
K02908  large subunit ribosomal protein L30e  -0.04 (-0.06 to -0.02)  0.030  
K03234  elongation factor 2  -0.04 (-0.06 to -0.02)  0.030  
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K06875  programmed cell death protein 5  -0.04 (-0.06 to -0.02)  0.030  
K08981  putative membrane protein  -0.04 (-0.06 to -0.02)  0.030  
K17884  archaetidylinositol phosphate synthase  -0.04 (-0.06 to -0.02)  0.030  
K00651  homoserine O-succinyltransferase/O-acetyltransferase  -0.04 (-0.06 to -0.02)  0.030  
K02885  large subunit ribosomal protein L19e  -0.04 (-0.06 to -0.02)  0.030  
K04518  prephenate dehydratase  -0.04 (-0.06 to -0.02)  0.030  
K06218  mRNA interferase RelE/StbE  -0.04 (-0.06 to -0.02)  0.030  
K06898  pyridinium-3,5-biscarboxylic acid mononucleotide synthase  -0.04 (-0.06 to -0.02)  0.030  
K07166  ACT domain-containing protein  -0.04 (-0.06 to -0.02)  0.030  
K18882  DNA primase large subunit  -0.04 (-0.06 to -0.02)  0.030  
K03047  DNA-directed RNA polymerase subunit D  -0.04 (-0.06 to -0.02)  0.032  
K16306  
fructose-bisphosphate aldolase / 2-amino-3,7-dideoxy-D-
threo-hept-6-ulosonate synthase  -0.04 (-0.06 to -0.02)  0.032  
K00611  ornithine carbamoyltransferase  -0.04 (-0.06 to -0.02)  0.033  
K09157  uncharacterized protein  -0.04 (-0.06 to -0.02)  0.033  
K00262  glutamate dehydrogenase (NADP+)  -0.04 (-0.06 to -0.02)  0.034  
K00319  methylenetetrahydromethanopterin dehydrogenase  -0.04 (-0.06 to -0.02)  0.034  
K01912  phenylacetate-CoA ligase  -0.04 (-0.06 to -0.02)  0.034  
K07727  putative transcriptional regulator  -0.04 (-0.06 to -0.02)  0.034  
K00058  
D-3-phosphoglycerate dehydrogenase / 2-oxoglutarate 
reductase  -0.04 (-0.06 to -0.02)  0.034  
K00177  2-oxoglutarate ferredoxin oxidoreductase subunit gamma  -0.04 (-0.06 to -0.02)  0.034  
K00179  indolepyruvate ferredoxin oxidoreductase, alpha subunit  -0.04 (-0.06 to -0.02)  0.034  
K00184  dimethyl sulfoxide reductase iron-sulfur subunit  -0.04 (-0.06 to -0.02)  0.034  
K00185  dimethyl sulfoxide reductase membrane subunit  -0.04 (-0.06 to -0.02)  0.034  
K00582  tetrahydromethanopterin S-methyltransferase subunit F  -0.04 (-0.06 to -0.02)  0.034  
K00818  acetylornithine aminotransferase  -0.04 (-0.06 to -0.02)  0.034  
K00930  acetylglutamate kinase  -0.04 (-0.06 to -0.02)  0.034  
K00940  nucleoside-diphosphate kinase  -0.04 (-0.06 to -0.02)  0.034  
K01012  biotin synthase  -0.04 (-0.06 to -0.02)  0.034  
K01091  phosphoglycolate phosphatase  -0.04 (-0.06 to -0.02)  0.034  
K01151  deoxyribonuclease IV  -0.04 (-0.06 to -0.02)  0.034  
K01421  putative membrane protein  -0.04 (-0.06 to -0.02)  0.034  
K01439  succinyl-diaminopimelate desuccinylase  -0.04 (-0.06 to -0.02)  0.034  
K01478  arginine deiminase  -0.04 (-0.06 to -0.02)  0.034  
K01482  dimethylargininase  -0.04 (-0.06 to -0.02)  0.034  
K01523  phosphoribosyl-ATP pyrophosphohydrolase  -0.04 (-0.06 to -0.02)  0.034  
K01693  imidazoleglycerol-phosphate dehydratase  -0.04 (-0.06 to -0.02)  0.034  
K01885  glutamyl-tRNA synthetase  -0.04 (-0.06 to -0.02)  0.034  
K02195  heme exporter protein C  -0.04 (-0.06 to -0.02)  0.034  
K02198  cytochrome c-type biogenesis protein CcmF  -0.04 (-0.06 to -0.02)  0.034  
K02203  phosphoserine / homoserine phosphotransferase  -0.04 (-0.06 to -0.02)  0.034  
K02282  pilus assembly protein CpaE  -0.04 (-0.06 to -0.02)  0.034  
K02319  DNA polymerase, archaea type  -0.04 (-0.06 to -0.02)  0.034  
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K02434  
aspartyl-tRNA(Asn)/glutamyl-tRNA(Gln) amidotransferase 
subunit B  -0.04 (-0.06 to -0.02)  0.034  
K02573  ferredoxin-type protein NapG  -0.04 (-0.06 to -0.02)  0.034  
K02574  ferredoxin-type protein NapH  -0.04 (-0.06 to -0.02)  0.034  
K02912  large subunit ribosomal protein L32e  -0.04 (-0.06 to -0.02)  0.034  
K02929  large subunit ribosomal protein L44e  -0.04 (-0.06 to -0.02)  0.034  
K02930  large subunit ribosomal protein L4e  -0.04 (-0.06 to -0.02)  0.034  
K03205  type IV secretion system protein VirD4  -0.04 (-0.06 to -0.02)  0.034  
K03385  nitrite reductase (cytochrome c-552)  -0.04 (-0.06 to -0.02)  0.034  
K03465  thymidylate synthase (FAD)  -0.04 (-0.06 to -0.02)  0.034  
K03498  trk system potassium uptake protein  -0.04 (-0.06 to -0.02)  0.034  
K03499  trk system potassium uptake protein  -0.04 (-0.06 to -0.02)  0.034  
K03540  ribonuclease P protein subunit RPR2  -0.04 (-0.06 to -0.02)  0.034  
K03655  ATP-dependent DNA helicase RecG  -0.04 (-0.06 to -0.02)  0.034  
K03758  arginine:ornithine antiporter / lysine permease  -0.04 (-0.06 to -0.02)  0.034  
K04041  fructose-1,6-bisphosphatase III  -0.04 (-0.06 to -0.02)  0.034  
K04655  hydrogenase expression/formation protein HypE  -0.04 (-0.06 to -0.02)  0.034  
K04656  hydrogenase maturation protein HypF  -0.04 (-0.06 to -0.02)  0.034  
K05780  
alpha-D-ribose 1-methylphosphonate 5-triphosphate 
synthase subunit PhnL  -0.04 (-0.06 to -0.02)  0.034  
K05781  putative phosphonate transport system ATP-binding protein  -0.04 (-0.06 to -0.02)  0.034  
K06163  alpha-D-ribose 1-methylphosphonate 5-phosphate C-P lyase  -0.04 (-0.06 to -0.02)  0.034  
K06914  tyramine---L-glutamate ligase  -0.04 (-0.06 to -0.02)  0.034  
K06915  uncharacterized protein  -0.04 (-0.06 to -0.02)  0.034  
K06963  tRNA acetyltransferase TAN1  -0.04 (-0.06 to -0.02)  0.034  
K07079  uncharacterized protein  -0.04 (-0.06 to -0.02)  0.034  
K07154  serine/threonine-protein kinase HipA  -0.04 (-0.06 to -0.02)  0.034  
K07307  anaerobic dimethyl sulfoxide reductase subunit B  -0.04 (-0.06 to -0.02)  0.034  
K07308  anaerobic dimethyl sulfoxide reductase subunit C  -0.04 (-0.06 to -0.02)  0.034  
K07309  Tat-targeted selenate reductase subunit YnfE  -0.04 (-0.06 to -0.02)  0.034  
K07580  Zn-ribbon RNA-binding protein  -0.04 (-0.06 to -0.02)  0.034  
K07776  
two-component system, OmpR family, response regulator 
RegX3  -0.04 (-0.06 to -0.02)  0.034  
K07979  GntR family transcriptional regulator  -0.04 (-0.06 to -0.02)  0.034  
K08372  putative serine protease PepD  -0.04 (-0.06 to -0.02)  0.034  
K08600  sortase B  -0.04 (-0.06 to -0.02)  0.034  
K08979  putative membrane protein  -0.04 (-0.06 to -0.02)  0.034  
K09121  
pyridinium-3,5-bisthiocarboxylic acid mononucleotide nickel 
chelatase  -0.04 (-0.06 to -0.02)  0.034  
K10040  
aspartate/glutamate/glutamine transport system permease 
protein  -0.04 (-0.06 to -0.02)  0.034  
K10206  LL-diaminopimelate aminotransferase  -0.04 (-0.06 to -0.02)  0.034  
K11176  IMP cyclohydrolase  -0.04 (-0.06 to -0.02)  0.034  
K11755  
phosphoribosyl-AMP cyclohydrolase / phosphoribosyl-ATP 
pyrophosphohydrolase  -0.04 (-0.06 to -0.02)  0.034  
K11913  type VI secretion system protein  -0.04 (-0.06 to -0.02)  0.034  
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K12257  SecD/SecF fusion protein  -0.04 (-0.06 to -0.02)  0.034  
K13252  putrescine carbamoyltransferase  -0.04 (-0.06 to -0.02)  0.034  
K13640  
MerR family transcriptional regulator, heat shock protein 
HspR  -0.04 (-0.06 to -0.02)  0.034  
K13812  bifunctional enzyme Fae/Hps  -0.04 (-0.06 to -0.02)  0.034  
K14088  ech hydrogenase subunit C  -0.04 (-0.06 to -0.02)  0.034  
K14188  D-alanine--poly(phosphoribitol) ligase subunit 2  -0.04 (-0.06 to -0.02)  0.034  
K15429  tRNA (guanine37-N1)-methyltransferase  -0.04 (-0.06 to -0.02)  0.034  
K16214  UDP-N-acetylglucosamine kinase  -0.04 (-0.06 to -0.02)  0.034  
K16793  methanogen homoaconitase small subunit  -0.04 (-0.06 to -0.02)  0.034  
K20265  glutamate:GABA antiporter  -0.04 (-0.06 to -0.02)  0.034  
K00145  N-acetyl-gamma-glutamyl-phosphate reductase  -0.04 (-0.06 to -0.01)  0.034  
K00176  2-oxoglutarate ferredoxin oxidoreductase subunit delta  -0.04 (-0.06 to -0.01)  0.034  
K00399  methyl-coenzyme M reductase alpha subunit  -0.04 (-0.06 to -0.01)  0.034  
K00613  glycine amidinotransferase  -0.04 (-0.06 to -0.01)  0.034  
K00666  fatty-acyl-CoA synthase  -0.04 (-0.06 to -0.01)  0.034  
K00846  ketohexokinase  -0.04 (-0.06 to -0.01)  0.034  
K01372  bleomycin hydrolase  -0.04 (-0.06 to -0.01)  0.034  
K01470  creatinine amidohydrolase  -0.04 (-0.06 to -0.01)  0.034  
K01661  naphthoate synthase  -0.04 (-0.06 to -0.01)  0.034  
K02069  putative ABC transport system permease protein  -0.04 (-0.06 to -0.01)  0.034  
K02435  
aspartyl-tRNA(Asn)/glutamyl-tRNA(Gln) amidotransferase 
subunit C  -0.04 (-0.06 to -0.01)  0.034  
K03521  electron transfer flavoprotein beta subunit  -0.04 (-0.06 to -0.01)  0.034  
K03552  holliday junction resolvase Hjr  -0.04 (-0.06 to -0.01)  0.034  
K03739  membrane protein involved in D-alanine export  -0.04 (-0.06 to -0.02)  0.034  
K04653  hydrogenase expression/formation protein HypC  -0.04 (-0.06 to -0.01)  0.034  
K05516  curved DNA-binding protein  -0.04 (-0.06 to -0.01)  0.034  
K06162  
alpha-D-ribose 1-methylphosphonate 5-triphosphate 
diphosphatase  -0.04 (-0.06 to -0.01)  0.034  
K07171  mRNA interferase MazF  -0.04 (-0.06 to -0.01)  0.034  
K07306  anaerobic dimethyl sulfoxide reductase subunit A  -0.04 (-0.06 to -0.02)  0.034  
K07402  xanthine dehydrogenase accessory factor  -0.04 (-0.06 to -0.01)  0.034  
K07562  nonsense-mediated mRNA decay protein 3  -0.04 (-0.06 to -0.01)  0.034  
K07581  RNA-binding protein  -0.04 (-0.06 to -0.02)  0.034  
K08177  MFS transporter, OFA family, oxalate/formate antiporter  -0.04 (-0.06 to -0.02)  0.034  
K08999  uncharacterized protein  -0.04 (-0.06 to -0.01)  0.034  
K09013  Fe-S cluster assembly ATP-binding protein  -0.04 (-0.06 to -0.01)  0.034  
K09167  uncharacterized protein  -0.04 (-0.06 to -0.01)  0.034  
K10536  agmatine deiminase  -0.04 (-0.06 to -0.01)  0.034  
K11358  aspartate aminotransferase  -0.04 (-0.06 to -0.02)  0.034  
K11912  serine/threonine-protein kinase PpkA  -0.04 (-0.06 to -0.01)  0.034  
K12136  hydrogenase-4 component A  -0.04 (-0.06 to -0.02)  0.034  
K12143  hydrogenase-4 component H  -0.04 (-0.06 to -0.02)  0.034  
K18926  MFS transporter, DHA2 family, lincomycin resistance protein  -0.04 (-0.06 to -0.01)  0.034  
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K08744  cardiolipin synthase (CMP-forming)  -0.04 (-0.06 to -0.01)  0.034  
K09790  uncharacterized protein  -0.04 (-0.06 to -0.01)  0.034  
K14086  ech hydrogenase subunit A  -0.04 (-0.06 to -0.01)  0.034  
K02322  DNA polymerase II large subunit  -0.04 (-0.06 to -0.01)  0.035  
K00123  formate dehydrogenase major subunit  -0.03 (-0.06 to -0.01)  0.035  
K01895  acetyl-CoA synthetase  -0.03 (-0.06 to -0.01)  0.035  
K01959  pyruvate carboxylase subunit A  -0.03 (-0.06 to -0.01)  0.035  
K02279  pilus assembly protein CpaB  -0.03 (-0.06 to -0.01)  0.035  
K02927  ubiquitin-large subunit ribosomal protein L40e  -0.04 (-0.06 to -0.01)  0.035  
K03231  elongation factor 1-alpha  -0.04 (-0.06 to -0.01)  0.035  
K03522  electron transfer flavoprotein alpha subunit  -0.03 (-0.06 to -0.01)  0.035  
K03783  purine-nucleoside phosphorylase  -0.03 (-0.06 to -0.01)  0.035  
K06982  pantoate kinase  -0.03 (-0.06 to -0.01)  0.035  
K07558  tRNA nucleotidyltransferase (CCA-adding enzyme)  -0.04 (-0.06 to -0.01)  0.035  
K09730  uncharacterized protein  -0.04 (-0.06 to -0.01)  0.035  
K11741  quaternary ammonium compound-resistance protein SugE  -0.03 (-0.06 to -0.01)  0.035  
K01814  
phosphoribosylformimino-5-aminoimidazole carboxamide 
ribotide isomerase  -0.03 (-0.06 to -0.01)  0.035  
K00053  ketol-acid reductoisomerase  -0.03 (-0.06 to -0.01)  0.035  
K00931  glutamate 5-kinase  -0.03 (-0.06 to -0.01)  0.035  
K02433  
aspartyl-tRNA(Asn)/glutamyl-tRNA(Gln) amidotransferase 
subunit A  -0.03 (-0.06 to -0.01)  0.035  
K02614  acyl-CoA thioesterase  -0.03 (-0.06 to -0.01)  0.035  
K02683  DNA primase small subunit  -0.03 (-0.06 to -0.01)  0.035  
K03151  tRNA uracil 4-sulfurtransferase  -0.03 (-0.06 to -0.01)  0.035  
K03622  archaea-specific DNA-binding protein  -0.03 (-0.06 to -0.01)  0.035  
K06206  sugar fermentation stimulation protein A  -0.03 (-0.06 to -0.01)  0.035  
K06921  uncharacterized protein  -0.03 (-0.06 to -0.01)  0.035  
K07164  uncharacterized protein  -0.03 (-0.06 to -0.01)  0.035  
K07452  5-methylcytosine-specific restriction enzyme B  -0.03 (-0.06 to -0.01)  0.035  
K09693  teichoic acid transport system ATP-binding protein  -0.03 (-0.06 to -0.01)  0.035  
K02922  large subunit ribosomal protein L37e  -0.03 (-0.06 to -0.01)  0.035  
K00052  3-isopropylmalate dehydrogenase  -0.03 (-0.05 to -0.01)  0.035  
K00286  pyrroline-5-carboxylate reductase  -0.03 (-0.05 to -0.01)  0.035  
K00817  histidinol-phosphate aminotransferase  -0.03 (-0.05 to -0.01)  0.035  
K00926  carbamate kinase  -0.03 (-0.05 to -0.01)  0.035  
K01129  dGTPase  -0.03 (-0.05 to -0.01)  0.035  
K01704  
3-isopropylmalate/(R)-2-methylmalate dehydratase small 
subunit  -0.03 (-0.05 to -0.01)  0.035  
K02042  phosphonate transport system permease protein  -0.03 (-0.05 to -0.01)  0.035  
K02068  putative ABC transport system ATP-binding protein  -0.03 (-0.05 to -0.01)  0.035  
K02653  type IV pilus assembly protein PilC  -0.03 (-0.05 to -0.01)  0.035  
K03313  Na+:H+ antiporter, NhaA family  -0.03 (-0.05 to -0.01)  0.035  
K03502  DNA polymerase V  -0.03 (-0.05 to -0.01)  0.035  
K03688  ubiquinone biosynthesis protein  -0.03 (-0.05 to -0.01)  0.035  
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K05919  superoxide reductase  -0.03 (-0.05 to -0.01)  0.035  
K06164  
alpha-D-ribose 1-methylphosphonate 5-triphosphate 
synthase subunit PhnI  -0.03 (-0.05 to -0.01)  0.035  
K06165  
alpha-D-ribose 1-methylphosphonate 5-triphosphate 
synthase subunit PhnH  -0.03 (-0.05 to -0.01)  0.035  
K06166  
alpha-D-ribose 1-methylphosphonate 5-triphosphate 
synthase subunit PhnG  -0.03 (-0.06 to -0.01)  0.035  
K06196  cytochrome c-type biogenesis protein  -0.03 (-0.05 to -0.01)  0.035  
K06972  presequence protease  -0.03 (-0.05 to -0.01)  0.035  
K07045  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.035  
K07126  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.035  
K07405  alpha-amylase  -0.03 (-0.05 to -0.01)  0.035  
K08659  dipeptidase  -0.03 (-0.05 to -0.01)  0.035  
K09773  [pyruvate, water dikinase]-phosphate phosphotransferase /  -0.03 (-0.06 to -0.01)  0.035  
K11928  sodium/proline symporter  -0.03 (-0.05 to -0.01)  0.035  
K12410  NAD-dependent deacetylase  -0.03 (-0.05 to -0.01)  0.035  
K14564  nucleolar protein 56  -0.03 (-0.06 to -0.01)  0.035  
K17828  dihydroorotate dehydrogenase (NAD+) catalytic subunit  -0.03 (-0.05 to -0.01)  0.035  
K17870  NADH oxidase (H2O2-forming)  -0.03 (-0.06 to -0.01)  0.035  
K03116  sec-independent protein translocase protein TatA  -0.03 (-0.05 to -0.01)  0.036  
K07220  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.036  
K16153  glycogen phosphorylase/synthase  -0.03 (-0.05 to -0.01)  0.036  
K19067  cyclohexane-1-carbonyl-CoA dehydrogenase  -0.03 (-0.05 to -0.01)  0.036  
K01733  threonine synthase  -0.03 (-0.05 to -0.01)  0.036  
K02654  leader peptidase (prepilin peptidase) / N-methyltransferase  -0.03 (-0.05 to -0.01)  0.036  
K03183  
demethylmenaquinone methyltransferase / 2-methoxy-6-
polyprenyl-1,4-benzoquinol methylase  -0.03 (-0.05 to -0.01)  0.036  
K03307  solute:Na+ symporter, SSS family  -0.03 (-0.05 to -0.01)  0.036  
K03340  diaminopimelate dehydrogenase  -0.03 (-0.05 to -0.01)  0.036  
K06943  nucleolar GTP-binding protein  -0.03 (-0.05 to -0.01)  0.036  
K06962  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.036  
K07446  tRNA (guanine10-N2)-dimethyltransferase  -0.03 (-0.05 to -0.01)  0.036  
K12511  tight adherence protein C  -0.03 (-0.05 to -0.01)  0.036  
K16792  methanogen homoaconitase large subunit  -0.03 (-0.05 to -0.01)  0.036  
K19955  alcohol dehydrogenase  -0.03 (-0.05 to -0.01)  0.036  
K07144  5-(aminomethyl)-3-furanmethanol phosphate kinase  -0.03 (-0.05 to -0.01)  0.036  
K01426  amidase  -0.03 (-0.05 to -0.01)  0.037  
K00174  
2-oxoglutarate/2-oxoacid ferredoxin oxidoreductase subunit 
alpha  -0.03 (-0.05 to -0.01)  0.037  
K00794  6,7-dimethyl-8-ribityllumazine synthase  -0.03 (-0.05 to -0.01)  0.037  
K01649  2-isopropylmalate synthase  -0.03 (-0.05 to -0.01)  0.037  
K01687  dihydroxy-acid dehydratase  -0.03 (-0.05 to -0.01)  0.037  
K02875  large subunit ribosomal protein L14e  -0.03 (-0.05 to -0.01)  0.037  
K03316  monovalent cation:H+ antiporter, CPA1 family  -0.03 (-0.05 to -0.01)  0.037  
K08963  methylthioribose-1-phosphate isomerase  -0.03 (-0.05 to -0.01)  0.037  
K03243  translation initiation factor 5B  -0.03 (-0.05 to -0.01)  0.037  
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K00147  glutamate-5-semialdehyde dehydrogenase  -0.03 (-0.05 to -0.01)  0.037  
K03722  ATP-dependent DNA helicase DinG  -0.03 (-0.05 to -0.01)  0.037  
K16926  
energy-coupling factor transport system substrate-specific 
component  -0.03 (-0.05 to -0.01)  0.037  
K02197  cytochrome c-type biogenesis protein CcmE  -0.03 (-0.05 to -0.01)  0.037  
K03242  translation initiation factor 2 subunit 3  -0.03 (-0.05 to -0.01)  0.037  
K08096  GTP cyclohydrolase IIa  -0.03 (-0.05 to -0.01)  0.037  
K18828  tRNA(fMet)-specific endonuclease VapC  -0.03 (-0.05 to -0.01)  0.037  
K03306  inorganic phosphate transporter, PiT family  -0.03 (-0.05 to -0.01)  0.038  
K15449  tRNA wybutosine-synthesizing protein 1  -0.03 (-0.05 to -0.01)  0.038  
K08352  thiosulfate reductase / polysulfide reductase chain A  -0.03 (-0.05 to -0.01)  0.038  
K10254  oleate hydratase  -0.03 (-0.05 to -0.01)  0.038  
K00313  electron transfer flavoprotein-quinone oxidoreductase  -0.03 (-0.05 to -0.01)  0.039  
K00442  coenzyme F420 hydrogenase subunit delta  -0.03 (-0.05 to -0.01)  0.039  
K00868  pyridoxine kinase  -0.03 (-0.05 to -0.01)  0.039  
K01710  dTDP-glucose 4,6-dehydratase  -0.03 (-0.05 to -0.01)  0.039  
K02564  glucosamine-6-phosphate deaminase  -0.03 (-0.05 to -0.01)  0.039  
K02669  twitching motility protein PilT  -0.03 (-0.05 to -0.01)  0.039  
K03639  GTP 3',8-cyclase  -0.03 (-0.05 to -0.01)  0.039  
K04751  nitrogen regulatory protein P-II 1  -0.03 (-0.05 to -0.01)  0.039  
K09138  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.039  
K12589  exosome complex component RRP42  -0.03 (-0.05 to -0.01)  0.039  
K15888  tritrans,polycis-undecaprenyl-diphosphate synthase  -0.03 (-0.05 to -0.01)  0.039  
K16785  energy-coupling factor transport system permease protein  -0.03 (-0.05 to -0.01)  0.039  
K00548  5-methyltetrahydrofolate--homocysteine methyltransferase  -0.03 (-0.05 to -0.01)  0.039  
K00764  amidophosphoribosyltransferase  -0.03 (-0.05 to -0.01)  0.039  
K01524  
exopolyphosphatase / guanosine-5'-triphosphate,3'-
diphosphate pyrophosphatase  -0.03 (-0.05 to -0.01)  0.039  
K01571  oxaloacetate decarboxylase (Na+ extruding) subunit alpha  -0.03 (-0.05 to -0.01)  0.039  
K02019  molybdate transport system regulatory protein  -0.03 (-0.05 to -0.01)  0.039  
K02283  pilus assembly protein CpaF  -0.03 (-0.05 to -0.01)  0.039  
K03427  type I restriction enzyme M protein  -0.03 (-0.05 to -0.01)  0.039  
K03620  Ni/Fe-hydrogenase 1 B-type cytochrome subunit  -0.03 (-0.05 to -0.01)  0.039  
K05837  rod shape determining protein RodA  -0.03 (-0.05 to -0.01)  0.039  
K06935  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.039  
K06953  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.039  
K08681  5'-phosphate synthase pdxT subunit  -0.03 (-0.05 to -0.01)  0.039  
K11041  exfoliative toxin A/B  -0.03 (-0.05 to -0.01)  0.039  
K11927  ATP-dependent RNA helicase RhlE  -0.03 (-0.05 to -0.01)  0.039  
K00762  orotate phosphoribosyltransferase  -0.03 (-0.05 to -0.01)  0.039  
K01006  pyruvate, orthophosphate dikinase  -0.03 (-0.05 to -0.01)  0.039  
K01499  methenyltetrahydromethanopterin cyclohydrolase  -0.03 (-0.05 to -0.01)  0.039  
K01653  acetolactate synthase I/III small subunit  -0.03 (-0.05 to -0.01)  0.039  
K01681  aconitate hydratase  -0.03 (-0.05 to -0.01)  0.039  
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K02823  dihydroorotate dehydrogenase electron transfer subunit  -0.03 (-0.05 to -0.01)  0.039  
K03051  DNA-directed RNA polymerase subunit F  -0.03 (-0.05 to -0.01)  0.039  
K05715  2-phosphoglycerate kinase  -0.03 (-0.05 to -0.01)  0.039  
K07533  foldase protein PrsA  -0.03 (-0.05 to -0.01)  0.039  
K15830  formate hydrogenlyase subunit 5  -0.03 (-0.05 to -0.01)  0.039  
K15669  
D-glycero-alpha-D-manno-heptose 1-phosphate 
guanylyltransferase  -0.03 (-0.05 to -0.01)  0.040  
K00789  S-adenosylmethionine synthetase  -0.03 (-0.05 to -0.01)  0.040  
K02217  ferritin  -0.03 (-0.05 to -0.01)  0.040  
K00555  tRNA (guanine26-N2/guanine27-N2)-dimethyltransferase  -0.03 (-0.05 to -0.01)  0.040  
K02017  molybdate transport system ATP-binding protein  -0.03 (-0.05 to -0.01)  0.040  
K06610  MFS transporter, SP family, inositol transporter  -0.03 (-0.05 to -0.01)  0.040  
K09153  small membrane protein  -0.03 (-0.05 to -0.01)  0.040  
K00003  homoserine dehydrogenase  -0.03 (-0.05 to -0.01)  0.041  
K00175  
2-oxoglutarate/2-oxoacid ferredoxin oxidoreductase subunit 
beta  -0.03 (-0.05 to -0.01)  0.041  
K00848  rhamnulokinase  -0.03 (-0.05 to -0.01)  0.041  
K01737  
6-pyruvoyltetrahydropterin/6-carboxytetrahydropterin 
synthase  -0.03 (-0.05 to -0.01)  0.041  
K01915  glutamine synthetase  -0.03 (-0.05 to -0.01)  0.041  
K01937  CTP synthase  -0.03 (-0.05 to -0.01)  0.041  
K02977  ubiquitin-small subunit ribosomal protein S27Ae  -0.03 (-0.05 to -0.01)  0.041  
K03106  signal recognition particle subunit SRP54  -0.03 (-0.05 to -0.01)  0.041  
K03150  2-iminoacetate synthase  -0.03 (-0.05 to -0.01)  0.041  
K03696  ATP-dependent Clp protease ATP-binding subunit ClpC  -0.03 (-0.05 to -0.01)  0.041  
K04773  protease IV  -0.03 (-0.05 to -0.01)  0.041  
K07569  RNA-binding protein  -0.03 (-0.05 to -0.01)  0.041  
K07704  
two-component system, LytTR family, sensor histidine kinase 
LytS  -0.03 (-0.05 to -0.01)  0.041  
K10117  
raffinose/stachyose/melibiose transport system substrate-
binding protein  -0.03 (-0.05 to -0.01)  0.041  
K14652  
3,4-dihydroxy 2-butanone 4-phosphate synthase / GTP 
cyclohydrolase II  -0.03 (-0.05 to -0.01)  0.041  
K18350  
two-component system, OmpR family, sensor histidine 
kinase VanS  -0.03 (-0.05 to -0.01)  0.041  
K18704  
CDP-ribitol ribitolphosphotransferase / teichoic acid ribitol-
phosphate polymerase  -0.03 (-0.05 to -0.01)  0.041  
K01493  dCMP deaminase  -0.03 (-0.05 to -0.01)  0.041  
K03856  3-deoxy-7-phosphoheptulonate synthase  -0.03 (-0.05 to -0.01)  0.041  
K07738  transcriptional repressor NrdR  -0.03 (-0.05 to -0.01)  0.041  
K09735  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.041  
K12240  pyochelin synthetase  -0.03 (-0.05 to -0.01)  0.041  
K14656  FAD synthetase  -0.03 (-0.05 to -0.01)  0.041  
K20859  
phosphoribosyl 1,2-cyclic phosphate 1,2-
diphosphodiesterase  -0.03 (-0.05 to -0.01)  0.041  
K09767  cyclic-di-GMP-binding protein  -0.03 (-0.05 to -0.01)  0.041  
K02567  nitrate reductase (cytochrome)  -0.03 (-0.05 to -0.01)  0.041  
K03627  putative transcription factor  -0.03 (-0.05 to -0.01)  0.041  
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K03646  colicin import membrane protein  -0.03 (-0.05 to -0.01)  0.041  
K19137  CRISPR-associated protein Csn2  -0.03 (-0.05 to -0.01)  0.041  
K01873  valyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.041  
K01874  methionyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.041  
K01939  adenylosuccinate synthase  -0.03 (-0.05 to -0.01)  0.041  
K03237  translation initiation factor 2 subunit 1  -0.03 (-0.05 to -0.01)  0.041  
K03602  exodeoxyribonuclease VII small subunit  -0.03 (-0.05 to -0.01)  0.041  
K07572  putative nucleotide binding protein  -0.03 (-0.05 to -0.01)  0.041  
K07334  toxin HigB-1  -0.03 (-0.05 to -0.01)  0.042  
K01938  formate--tetrahydrofolate ligase  -0.03 (-0.05 to -0.01)  0.042  
K04654  hydrogenase expression/formation protein HypD  -0.03 (-0.05 to -0.01)  0.042  
K00031  isocitrate dehydrogenase  -0.03 (-0.05 to -0.01)  0.042  
K06937  7,8-dihydro-6-hydroxymethylpterin dimethyltransferase  -0.03 (-0.05 to -0.01)  0.042  
K00125  formate dehydrogenase (coenzyme F420) beta subunit  -0.03 (-0.05 to -0.01)  0.042  
K00891  shikimate kinase  -0.03 (-0.05 to -0.01)  0.042  
K01740  O-acetylhomoserine (thiol)-lyase  -0.03 (-0.05 to -0.01)  0.042  
K01868  threonyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.042  
K02551  
2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-
carboxylate synthase  -0.03 (-0.05 to -0.01)  0.042  
K03282  large conductance mechanosensitive channel  -0.03 (-0.05 to -0.01)  0.042  
K04517  prephenate dehydrogenase  -0.03 (-0.05 to -0.01)  0.042  
K07076  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.042  
K18918  
RHH-type transcriptional regulator, rel operon repressor / 
antitoxin RelB  -0.03 (-0.05 to -0.01)  0.042  
K00991  2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase  -0.03 (-0.05 to -0.01)  0.042  
K01170  tRNA-intron endonuclease, archaea type  -0.03 (-0.05 to -0.01)  0.042  
K04652  hydrogenase nickel incorporation protein HypB  -0.03 (-0.05 to -0.01)  0.043  
K03057  transcription factor S  -0.03 (-0.05 to -0.01)  0.043  
K07134  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.043  
K01883  cysteinyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.044  
K00077  2-dehydropantoate 2-reductase  -0.03 (-0.05 to -0.01)  0.044  
K00443  coenzyme F420 hydrogenase subunit gamma  -0.03 (-0.05 to -0.01)  0.044  
K01579  aspartate 1-decarboxylase  -0.03 (-0.05 to -0.01)  0.044  
K01755  argininosuccinate lyase  -0.03 (-0.05 to -0.01)  0.044  
K02323  DNA polymerase II small subunit  -0.03 (-0.05 to -0.01)  0.044  
K05934  precorrin-3B C17-methyltransferase  -0.03 (-0.05 to -0.01)  0.044  
K09141  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.044  
K11717  cysteine desulfurase / selenocysteine lyase  -0.03 (-0.05 to -0.01)  0.044  
K09724  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.044  
K01104  protein-tyrosine phosphatase  -0.03 (-0.05 to -0.01)  0.044  
K03055  DNA-directed RNA polymerase subunit K  -0.03 (-0.05 to -0.01)  0.044  
K03687  molecular chaperone GrpE  -0.03 (-0.05 to -0.01)  0.044  
K01155  type II restriction enzyme  -0.03 (-0.05 to -0.01)  0.044  
K03421  methyl-coenzyme M reductase subunit C  -0.03 (-0.05 to -0.01)  0.044  
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K19545  lincosamide nucleotidyltransferase A/C/D/E  -0.03 (-0.05 to -0.01)  0.044  
K00793  riboflavin synthase  -0.03 (-0.05 to -0.01)  0.045  
K04766  acetoin utilization protein AcuA  -0.03 (-0.05 to -0.01)  0.045  
K08972  putative membrane protein  -0.03 (-0.05 to -0.01)  0.045  
K04043  molecular chaperone DnaK  -0.03 (-0.05 to -0.01)  0.045  
K11131  H/ACA ribonucleoprotein complex subunit 4  -0.03 (-0.05 to -0.01)  0.045  
K01265  methionyl aminopeptidase  -0.03 (-0.05 to -0.01)  0.045  
K02492  glutamyl-tRNA reductase  -0.03 (-0.05 to -0.01)  0.045  
K02988  small subunit ribosomal protein S5  -0.03 (-0.05 to -0.01)  0.045  
K03310  alanine or glycine:cation symporter, AGCS family  -0.03 (-0.05 to -0.01)  0.045  
K03534  L-rhamnose mutarotase  -0.03 (-0.05 to -0.01)  0.045  
K03686  molecular chaperone DnaJ  -0.03 (-0.05 to -0.01)  0.045  
K06147  ATP-binding cassette, subfamily B, bacterial  -0.03 (-0.05 to -0.01)  0.045  
K06862  energy-converting hydrogenase B subunit Q  -0.03 (-0.05 to -0.01)  0.045  
K08316  16S rRNA (guanine966-N2)-methyltransferase  -0.03 (-0.05 to -0.01)  0.045  
K07271  lipopolysaccharide cholinephosphotransferase  -0.03 (-0.05 to -0.01)  0.045  
K09726  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.045  
K14128  F420-non-reducing hydrogenase small subunit  -0.03 (-0.05 to -0.01)  0.045  
K00600  glycine hydroxymethyltransferase  -0.03 (-0.05 to -0.01)  0.046  
K09714  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.046  
K00590  site-specific DNA-methyltransferase (cytosine-N4-specific)  -0.03 (-0.05 to -0.01)  0.046  
K01866  tyrosyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.046  
K03637  cyclic pyranopterin monophosphate synthase  -0.03 (-0.05 to -0.01)  0.046  
K05896  segregation and condensation protein A  -0.03 (-0.05 to -0.01)  0.046  
K07310  Tat-targeted selenate reductase subunit YnfF  -0.03 (-0.05 to -0.01)  0.046  
K14113  energy-converting hydrogenase B subunit D  -0.03 (-0.05 to -0.01)  0.046  
K14125  energy-converting hydrogenase B subunit P  -0.03 (-0.05 to -0.01)  0.046  
K19147  5-methylcytosine-specific restriction enzyme subunit McrC  -0.03 (-0.05 to -0.01)  0.046  
K01179  endoglucanase  -0.03 (-0.05 to -0.01)  0.046  
K01872  alanyl-tRNA synthetase  -0.03 (-0.05 to -0.01)  0.046  
K03976  Cys-tRNA(Pro)/Cys-tRNA(Cys) deacylase  -0.03 (-0.05 to -0.01)  0.046  
K06200  carbon starvation protein  -0.03 (-0.05 to -0.01)  0.046  
K07030  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.046  
K14111  energy-converting hydrogenase B subunit B  -0.03 (-0.05 to -0.01)  0.046  
K14116  energy-converting hydrogenase B subunit G  -0.03 (-0.05 to -0.01)  0.046  
K14119  energy-converting hydrogenase B subunit J  -0.03 (-0.05 to -0.01)  0.046  
K14120  energy-converting hydrogenase B subunit K  -0.03 (-0.05 to -0.01)  0.046  
K14122  energy-converting hydrogenase B subunit M  -0.03 (-0.05 to -0.01)  0.046  
K14123  energy-converting hydrogenase B subunit N  -0.03 (-0.05 to -0.01)  0.046  
K00440  coenzyme F420 hydrogenase subunit alpha  -0.03 (-0.05 to -0.01)  0.046  
K02035  peptide/nickel transport system substrate-binding protein  -0.03 (-0.05 to -0.01)  0.046  
K02189  cobalt-precorrin 5A hydrolase  -0.03 (-0.05 to -0.01)  0.046  
K02866  large subunit ribosomal protein L10e  -0.03 (-0.05 to -0.01)  0.046  
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K07111  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.046  
K20021  L-cysteine desulfidase  -0.03 (-0.05 to -0.01)  0.046  
K00244  fumarate reductase flavoprotein subunit  -0.03 (-0.05 to -0.01)  0.046  
K03042  DNA-directed RNA polymerase subunit A"  -0.03 (-0.05 to -0.01)  0.047  
K06920  7-cyano-7-deazaguanine synthase  -0.03 (-0.05 to -0.01)  0.047  
K12297  
23S rRNA (guanine2445-N2)-methyltransferase / 23S rRNA 
(guanine2069-N7)-methyltransferase  -0.03 (-0.05 to -0.01)  0.047  
K00219  2,4-dienoyl-CoA reductase (NADPH2)  -0.03 (-0.05 to -0.01)  0.047  
K00239  
succinate dehydrogenase / fumarate reductase, flavoprotein 
subunit  -0.03 (-0.05 to -0.01)  0.047  
K01425  glutaminase  -0.03 (-0.05 to -0.01)  0.047  
K01738  cysteine synthase  -0.03 (-0.05 to -0.01)  0.047  
K02906  large subunit ribosomal protein L3  -0.03 (-0.05 to -0.01)  0.047  
K04651  hydrogenase nickel incorporation protein HypA/HybF  -0.03 (-0.05 to -0.01)  0.047  
K07068  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.047  
K09721  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.047  
K09732  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.047  
K09742  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.047  
K10553  fructose transport system permease protein  -0.03 (-0.05 to -0.01)  0.047  
K14110  energy-converting hydrogenase B subunit A  -0.03 (-0.05 to -0.01)  0.047  
K14112  energy-converting hydrogenase B subunit C  -0.03 (-0.05 to -0.01)  0.047  
K14114  energy-converting hydrogenase B subunit E  -0.03 (-0.05 to -0.01)  0.047  
K14115  energy-converting hydrogenase B subunit F  -0.03 (-0.05 to -0.01)  0.047  
K14121  energy-converting hydrogenase B subunit L  -0.03 (-0.05 to -0.01)  0.047  
K14124  energy-converting hydrogenase B subunit O  -0.03 (-0.05 to -0.01)  0.047  
K15773  HTH-type transcriptional regulator / antitoxin HipB  -0.03 (-0.05 to -0.01)  0.047  
K00558  DNA (cytosine-5)-methyltransferase 1  -0.03 (-0.05 to -0.01)  0.047  
K02548  1,4-dihydroxy-2-naphthoate polyprenyltransferase  -0.03 (-0.05 to -0.01)  0.047  
K02570  periplasmic nitrate reductase NapD  -0.03 (-0.05 to -0.01)  0.047  
K02881  large subunit ribosomal protein L18  -0.03 (-0.05 to -0.01)  0.048  
K02907  large subunit ribosomal protein L30  -0.03 (-0.05 to -0.01)  0.048  
K03969  phage shock protein A  -0.03 (-0.05 to -0.01)  0.048  
K08357  tetrathionate reductase subunit A  -0.03 (-0.05 to -0.01)  0.048  
K01520  dUTP pyrophosphatase  -0.03 (-0.05 to -0.01)  0.048  
K01547  potassium-transporting ATPase ATP-binding subunit  -0.03 (-0.05 to -0.01)  0.048  
K00609  aspartate carbamoyltransferase catalytic subunit  -0.03 (-0.05 to -0.01)  0.048  
K01588  5-(carboxyamino)imidazole ribonucleotide mutase  -0.03 (-0.05 to -0.01)  0.048  
K03168  DNA topoisomerase I  -0.03 (-0.05 to -0.01)  0.048  
K11175  phosphoribosylglycinamide formyltransferase 1  -0.03 (-0.05 to -0.01)  0.048  
K03330  glutamyl-tRNA(Gln) amidotransferase subunit E  -0.03 (-0.05 to -0.01)  0.048  
K03529  chromosome segregation protein  -0.03 (-0.05 to -0.01)  0.048  
K03750  molybdopterin molybdotransferase  -0.03 (-0.05 to -0.01)  0.048  
K07812  trimethylamine-N-oxide reductase (cytochrome c)  -0.03 (-0.05 to -0.01)  0.048  
K18209  fumarate reductase (CoM/CoB) subunit A  -0.03 (-0.05 to -0.01)  0.048  
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K07458  DNA mismatch endonuclease, patch repair protein  -0.03 (-0.05 to -0.01)  0.048  
K00567  methylated-DNA-[protein]-cysteine S-methyltransferase  -0.03 (-0.05 to -0.01)  0.049  
K01011  thiosulfate/3-mercaptopyruvate sulfurtransferase  -0.03 (-0.05 to -0.01)  0.049  
K14392  sodium/pantothenate symporter  -0.03 (-0.05 to -0.01)  0.049  
K01153  type I restriction enzyme, R subunit  -0.03 (-0.05 to -0.01)  0.049  
K01756  adenylosuccinate lyase  -0.03 (-0.05 to -0.01)  0.049  
K02982  small subunit ribosomal protein S3  -0.03 (-0.05 to -0.01)  0.049  
K03166  DNA topoisomerase VI subunit A  -0.03 (-0.05 to -0.01)  0.049  
K07096  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.049  
K08298  L-carnitine CoA-transferase  -0.03 (-0.05 to -0.01)  0.049  
K09482  glutamyl-tRNA(Gln) amidotransferase subunit D  -0.03 (-0.05 to -0.01)  0.049  
K10896  fanconi anemia group M protein  -0.03 (-0.05 to -0.01)  0.049  
K11212  LPPG:FO 2-phospho-L-lactate transferase  -0.03 (-0.05 to -0.01)  0.049  
K14982  
two-component system, OmpR family, sensor histidine 
kinase CiaH  -0.03 (-0.05 to -0.01)  0.049  
K15731  
carboxy-terminal domain RNA polymerase II polypeptide A 
small phosphatase  -0.03 (-0.05 to -0.01)  0.049  
K18830  HTH-type transcriptional regulator / antitoxin PezA  -0.03 (-0.05 to -0.01)  0.049  
K00763  nicotinate phosphoribosyltransferase  -0.03 (-0.05 to -0.01)  0.049  
K12141  hydrogenase-4 component F  -0.03 (-0.05 to -0.01)  0.049  
K01546  potassium-transporting ATPase potassium-binding subunit  -0.03 (-0.05 to -0.01)  0.049  
K02933  large subunit ribosomal protein L6  -0.03 (-0.05 to -0.01)  0.049  
K07442  
tRNA (adenine57-N1/adenine58-N1)-methyltransferase 
catalytic subunit  -0.03 (-0.05 to -0.01)  0.049  
K02904  large subunit ribosomal protein L29  -0.03 (-0.05 to -0.01)  0.049  
K06913  uncharacterized protein  -0.03 (-0.05 to -0.01)  0.049  
K01975  RNA 2',3'-cyclic 3'-phosphodiesterase  -0.03 (-0.05 to -0.01)  0.049  
K02994  small subunit ribosomal protein S8  -0.03 (-0.05 to -0.01)  0.049  
K06019  pyrophosphatase PpaX  -0.03 (-0.05 to -0.01)  0.050  
K07114  Ca-activated chloride channel homolog  -0.03 (-0.05 to -0.01)  0.050  
 
P values are adjusted for multiple testing using FDR correction. 
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Figure S1. Associations between Lactobacilli and blood pressure by sex. 
 
 
The models are adjusted for age, BMI, smoking, exercise, diuretics, beta blockers, 
calcium channel blockers, and renin–angiotensin system blockers. N=3 819 for 
women and N=3 134 for men. BP, Blood pressure; MAP, Mean arterial pressure. 
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Figure S2. Associations between Lactobacilli and blood pressure by 
antihypertensive medication use. 
 
 
The models are adjusted for age, sex, BMI, smoking, exercise, diuretics, beta 
blockers, calcium channel blockers, and renin–angiotensin system blockers. 
Association with bacterial plasmid is denoted using asterisk. N=1 253 for 
antihypertensive medication users and N=5 700 for non-users. BP, Blood pressure; 
MAP, Mean arterial pressure. 
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Figure S3. Functional pathways associated with systolic BP. 
 
  
 
For the module (cyan), pathway (purple), biological process (dark brown), and 
biological category (light brown) functional layers, node size corresponds to the 
average inverse P value of the KO group assigned to that node. Only KO groups that 
were negatively associated with systolic BP were included. Node titles are shown for 
nodes in the three highest layers with a size > 200. 
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